The role of MEF2C in endothelial cells by Sturtzel, Caterina
 
 
 
 
 
 
 
 
 
 
DIPLOMARBEIT 
 
 
 
 
Titel der Diplomarbeit 
 
 
 
The role of MEF2C in endothelial cells 
 
 
 
 
 
 
angestrebter akademischer Grad 
 
Magistra der Naturwissenschaften (Mag. rer.nat.)  
 
 
 
 
 
Verfasserin / Verfasser: Caterina Sturtzel 
Matrikel-Nummer: 0101289 
Studienrichtung (lt. 
Studienblatt): 
Molekulare Biologie 
Betreuerin / Betreuer: Prof. Erhard Hofer 
 
 
 
 
Wien, im  November 2007 
 
 
 
 
 
The role of MEF2C in endothelial cells 
 2
 
Danksagung: 
 
Ich möchte mich an dieser Stelle bei Prof. Dr. Erhard Hofer bedanken, dass er 
mir die Möglichkeit gab, meine Diplomarbeit zu einem interessanten Thema 
verfassen zu können, und mich dabei stets unterstützt hat.  
 
Dank gilt auch meinen Studiums- und Labor- KollegInnen Mag. Silvia Bicker, 
Mag. Julia Schultes, Mag. Irene Michl, Mag. Susanne Sattler, Dipl.-Biol. Dorit 
Reiche, Maria Witkowski und Mag. Bernhard Schweighofer, die mir immer 
mit Rat und Tat zur Seite standen.  
 
Ganz besonders bedanken möchte ich mich bei meiner Mutter Dr. Bärbel 
Sturtzel, ohne die ich heute nicht dort wäre, wo ich bin. Ich war froh über 
jedes Essen, jeden Kaffee und jeden Tee, über allen seelischen Beistand und 
auch über alle wissenschaftlichen Gespräche! 
 
Meinem Bruder Florian gebührt Dank für seine Geduld. 
 
Erwähnt sollen auch meine Tiere sein, Bibi, Coco, Perla und Tabaluga, für all 
die Lebensfreude, die sie mir schenkten.  
 
 
 
 
 
 
 
 
 
 
 
 
The role of MEF2C in endothelial cells 
 3
Contents: 
I. Introduction:............................................................................................................5 
I.1. Vasculogenesis, Angiogenesis and Lymphangiogenesis: ............................. 5 
I.2. Angiogenesis in disease:......................................................................................... 8 
I.3. Triggering angiogenesis: ......................................................................................... 9 
I.4. VEGF and its receptors: ........................................................................................... 9 
I.5. DNA Microarray – VEGF versus EGF versus IL-1 ............................................ 12 
I.6. MEF2C:........................................................................................................................ 13 
I.6.1 The pedigree of MEF2C: ......................................................................................................13 
I.6.2. MEF2 regulation by HDACs:...............................................................................................14 
I.6.3. Ca2+ dependent MEF2 regulation: .....................................................................................15 
I.6.4. MAPK dependent MEF2 regulation:..................................................................................16 
I.6.5. Posttranslational modifications:..........................................................................................17 
I.6.6. MEF2C cell expression pattern: .........................................................................................18 
I.6.7. MEF2C in angiogenesis: .....................................................................................................18 
I.7. Adenovirus: ............................................................................................................... 20 
II. Materials and Methods:.....................................................................................23 
II.1. Vectors and Plasmids:........................................................................................... 23 
II.2. Primers: ..................................................................................................................... 24 
II.3. Restriction endonucleases and DNA modifying enzymes: ......................... 25 
II.4. Antibodies (Western blot):.................................................................................... 25 
II.5. Cells:........................................................................................................................... 25 
II.5.1 HUVEC: ..................................................................................................................................25 
II.5.2 293 cells: ................................................................................................................................26 
II.6. Bacterial Cultures: .................................................................................................. 27 
II.7. Agarose gel electrophoresis:............................................................................... 28 
II.8. Protein analysis:...................................................................................................... 28 
II.8.1. SDS- Polyacrylamid Gel separation:................................................................................28 
II.8.2. Western blot:.........................................................................................................................29 
II.8.3 Evaluation of Blot: .................................................................................................................30 
II.9. Real Time Reverse Transcription Polymerase Chain Reaction:................. 31 
II.9.1. Total RNA Isolation: ............................................................................................................31 
II.9.2. cDNA Synthesis: ..................................................................................................................31 
II.9.4. Quantitative Real Time PCR: ............................................................................................32 
II.9.5. Primer design: ......................................................................................................................33 
II.10. Plasmid DNA assignments: ............................................................................... 34 
II.11. Production of a recombinant Adenovirus:..................................................... 38 
II.11.2. Expansion of recombinant Adenovirus:.........................................................................40 
II.11.3. CsCl purification:................................................................................................................41 
II.11.4. Titration of Virus:................................................................................................................41 
II.11.5. Sequencing of the virus:...................................................................................................42 
II.12. FACS analysis: ...................................................................................................... 42 
II.13. Matrigel- Assay:..................................................................................................... 42 
II.14. Sprouting Assay: .................................................................................................. 43 
The role of MEF2C in endothelial cells 
 4
III. Aims: .....................................................................................................................44 
IV. Results:................................................................................................................45 
IV.1. Verification of MEF2C induction by VEGF in HUVEC: ................................. 45 
IV.2. Generation of a MEF2C Adenovirus:................................................................ 46 
IV.3. Determination of optimal MOI (Multiplicity of Infection): ............................ 49 
IV.4. Overexpression of MEF2C: ................................................................................. 51 
IV.5. Influence of MEF2C on VEGF-mediated gene induction in HUVEC ......... 53 
IV.6. In vitro Angiogenesis Assays: ........................................................................... 56 
V. Discussion: ..........................................................................................................59 
V.1. MEF2C is specifically upregulated by VEGF:.................................................. 59 
V.2. The experimental tool adenovirus: .................................................................... 60 
V.3. Influence of MEF2C on VEGF induced genes:................................................ 63 
V.4. Angiogenesis assays: ........................................................................................... 65 
VI. References:.........................................................................................................68 
VII. Appendix: ...........................................................................................................73 
VII.1. Vectors: ................................................................................................................... 73 
VII.1.1. pShuttle-IRES-hrGFP-1 ...................................................................................................73 
VII.1.2. pAdEasy-1:.........................................................................................................................74 
VII.1.3. pBluescriptR-IRATp970F1023D: ...................................................................................75 
VII.1.4. pShuttle-CMV-MEF2C-IRES-hrGFP: ............................................................................76 
VII.2. Sequences: ............................................................................................................ 76 
VII.2.1. Amino Acid sequence of MEF2C: ..................................................................................76 
VII.2.2 Sequence of the MEF2C virus construct: ......................................................................77 
VII.3. Markers: .................................................................................................................. 78 
VII.3.1. DNA Markers: 1kb DNA ladder and Lambda DNA/Eco91I (BstEII) digest.............78 
VII.3.2 Protein Marker: ...................................................................................................................78 
VII.4. Abbreviations: ....................................................................................................... 79 
VIII. Table of Figures: .............................................................................................80 
„ Curriculum vitae “................................................................................................81 
Summary: ..................................................................................................................82 
Zusammenfassung:................................................................................................83 
 
 
 
 
 
 
 
 
 
 
 
 
The role of MEF2C in endothelial cells 
 5
 
I. Introduction: 
 
I.1. Vasculogenesis, Angiogenesis and Lymphangiogenesis: 
 
The intricate body architecture of vertebrates makes high-capacity transport of 
gases, liquids, nutrients, signalling molecules and circulating cells between 
tissues and organs necessary. Two highly branched tubular networks 
constituted by endothelial cells are in duty of mediating this vital metabolic 
exchange between tissues and blood; the blood and the lymphatic vessels 
(Adams and Alitalo, 2007). The development of the vascular system is a 
complicated process governed by the concerted action of many genes (Bi et 
al., 1999).  
Chronologically, vessel morphogenesis occurs in three distinct mechanisms: 
vasculogenesis, angiogenesis and lymphangiogenesis (Adams and Alitalo, 
2007). Carmeliet additionally defines arteriogenesis as the stabilisation of 
angiogenic sprouts by mural cells, like pericytes for medium-seized and 
smooth muscle cells for large-seized vessels (Carmeliet, 2004).  
 
 
Figure 1: Assembly of the vasculature (Adams and Alitalo, 2007) 
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During vasculogenesis angioblasts, the precursors of endothelial cells, 
establish a primitive vascular network through aggregation and successive 
lumen formation into cord-like structures (Bi et al., 1999). Extracellular matrix 
(ECM) is produced by mural cells and provides a framework and bed for the 
dynamic installation processes. Subsequently, based on this starting points, 
events of matrix remodelling by MMP (matrix metallo proteinases) and of 
extension of the nascent vessels by sprouting shape a mature vascular 
network, a process referred to as angiogenesis (Carmeliet, 2004).  
 
Principally, arteries and veins expand through circumferential growth to 
increase blood transport capacity, whereas capillaries sprout and ramify into 
complex networks, thereby facilitating exchange of gases like oxygen (Adams 
and Alitalo, 2007). Notwithstanding, angiogenesis also plays a role in the 
mature organism, contributing to organ growth and wound healing (Carmeliet, 
2005).  
Contact face of the two vessel systems is the largest lymphatic vessel, the 
thoracic duct, where lymph is drained into the blood circulation (Adams and 
Alitalo, 2007) (Figure 1). Lymph vessels transdifferentiate from veins 
stimulated by the growth factor VEGF-C (Alitalo et al., 2005).  
Arterial or venous fates of angioblasts are sealed very early under the 
influence of VEGF and are thought to be irreversible. Previous to this 
determination, endothelial progenitors themselves are very versatile in regard 
of their potential differentiation capacitiy. In the developing embryo precursors 
were identified that can either give rise to only endothelial cells (EC), 
angioblasts, or ECs and blood cells, haemangioblasts (Carmeliet, 2000). In 
contrast, adult neovascularization depends on circulating not local endothelial 
progenitor cells, mobilized from the bone marrow. They are incorporated at 
distant organs in a VEGF dependent way (Rafii and Lyden, 2003).  
 
In the embryo, initially under control of TGF-ß1 and succeedingly PDGF-BB, 
smooth muscle progenitors which originated from mesenchymal cells, neural 
crest or epicardial cells are recruited to cover newly branched channels 
(Carmeliet, 2000). Furthermore, potential common vascular progenitors were 
found. These VEGFR-2 positive precursors are either sent along the 
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developmental pathway to become ECs in response to VEGF or forced into 
becoming smooth muscle cells by PDGF-BB (Yamashita et al., 2000) (Figure 
2). 
 
 
 
 
Figure 2: Vascular Progenitors (Carmeliet, 2004) 
During vascular delopment in the embryo endothelial, smooth muscle and common vascular 
progenitor cells interact. In the adult endothelial and smooth muscle progenitors were shown 
to be derived from the bone marrow. 
 
 
Moreover, another important mural cell recruiting mechanism is the Ang-1/ 
Tie2 system. EC receptor tyrosine kinase Tie2 signalling upon Ang1- binding, 
which is secreted from surrounding tissue, also mediates mature vessel wall 
formation (Cleaver and Melton, 2003). 
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I.2. Angiogenesis in disease:  
 
Balanced and well synchronized angiogenesis, as the basis for a functional 
endothelium, highly contributes to the homoeostasis of an organism. 
Unfortunately, when this system gets out of control it may also contribute to a 
variety of diseases (Galley and Webster, 2004). It seems reasonable that 
excessive vessel growth as well as impaired blood vessel supply leads to a 
variety of ailments. Prominent disorders are arthritis, psoriasis, retinopathies, 
angina pectoris, arthrosclerosis and cancer. Indeed, the list is much longer, 
including hypertension, restenosis, obesity, complications in diabetes, heart 
and brain ischemia, dermatitis and many more (Carmeliet, 2004). 
Consequently, an urgent need of therapeutics to cure these diseases prevails. 
To obtain new therapeutic targets elucidation of the underlying mechanisms of 
angiogenesis is essential.  
 
Recently, one research focus was on tumour angiogenesis. The first approach 
to stop tumour growth was to attempt to block initiation of angiogenesis by 
administration of an antibody against the major angiogenic growth factor 
VEGF with the goal to achieve starvation of the tumour. Experiments, 
designed to block VEGF, revealed tumour angiogenesis is a much more 
complex affair than initially anticipated (Ferrara and Kerbel, 2005).  
Tumour vasculature differs significantly from the vasculature of healthy 
individuals. It is unorganized, has branches of uneven diameters, vessel walls 
are interrupted and highly fenestrated and they are often incapable of blood 
transportation (Fukumura and Jain, 2007). It is still controversial whether 
tumour angiogenesis is cause or consequence of cancer; the question is 
whether the tumour recruits novel vasculature actively or does uncontrolled 
upregulation of genes coincidently provoke the “angiogenic switch”? 
Therefore, distinct choice of either stabilization of tumour vessels for the sake 
of an enhanced transport of cytotoxic therapeutics to the tumour, or growth 
inhibition of vessels in order to starve the tumour will individually decide over 
the outcome of the therapy (Shchors and Evan, 2007). 
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I.3. Triggering angiogenesis: 
 
Generally, beside NO hypoxia is the classical trigger of angiogenesis. When 
the vascular system is ruptured, for example in wounded tissue, new blood 
vessels have to be rebuilt rapidly. Hypoxia, caused by injury or present in the 
pathologically dys-structured environment of tumours, is sensed by the protein 
HIF (hypoxia inducible factor).  
In oxygenated cells this transcription factor is kept in check by two separate, 
elaborated mechanisms. Oxygen-dependent hydroxylation marks this protein 
for ubiquitin-dependent degradation and prevents association with a 
transcriptional coactivator. Under hypoxic conditions these regulatory 
mechanisms fail and HIF becomes transcriptionally active, which leads (in 
addition to several other cellular responses) to the release of angiogenic 
factors, like bFGF, PlGF or VEGF (Pugh and Ratcliffe, 2003). 
 
I.4. VEGF and its receptors: 
 
VEGF (vascular endothelial growth factor) was discovered and isolated from a 
solid tumour in the late 80ies and initially named vascular permeability factor, 
because it was the most potent enhancer of vascular leakage of the skin 
known so far (Ferrara et al., 2003). 
VEGF-A is regarded as the major angiogenic factor. It is important for blood 
vessel angiogenesis and vasculogenesis. VEGF-A, VEGF-B, VEGF-C, VEGF-
D and VEGF-E and PlGF belong to a glycoprotein superfamily of growth 
factors.  
VEGF-A particularly contributes to blood vessel growth, whereas VEGF-C and 
VEGF-D, which have to be especially activated by proteolysis, are the key 
regulators of lymphangiogenesis (Byrne et al., 2005). As VEGF-B-/- mice are 
viable and only exhibit a weak heart phenotype, its role remains obscure as 
well as the function of the receptor VEGFR-1 (Takahashi and Shibuya, 2005). 
VEGF-E is produced by the human parapox orf virus and has similar 
biological activity as VEGF-A165 (Takahashi and Shibuya, 2005), emphasising 
the potentially mitogenic capacity of this growth factor. PlGF only binds to 
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VEGFR-1, thereby exerting an blocking function (Takahashi and Shibuya, 
2005).  
Five different isoforms of VEGF-A are identified (Byrne et al., 2005). They 
result from alternative splicing of the eight exons and seven introns, the 
VEGFA gene is separated in. VEGF121, VEGF145, VEGF165, VEGF189 and 
VEGF206 consist of 121, 145, 165, 189 and 206 amino acids respectively. 
They are distinguished by their altered capability of heparin binding. Whereas 
VEGF189 and 206 are nearly completely absorbed and sequestered by the 
ECM, VEGF121 is highly diffusible (Byrne et al., 2005; Ferrara et al., 2003). 
However, the intermediate 165, which is secreted but remains bound to the 
cell surface as well, seems to be the predominant form featuring the optimal 
characteristics of bioavailability (loss of heparin-binding domain renders the 
protein mitogenically inactive) and biological potency (as only VEGF165 
knockout seems to be really detrimental to the mice) (Ferrara, 2004). By 
plasmin cleavage of VEGF189 sequestered in the ECM a biologically active 
form of VEGF might also be released, thereby contributing to the local 
availability of VEGF (Figure 3). 
During hypoxia binding of the proteins HuR (RNA binding protein) and PAIP2 
(Poly-(A)-binding protein) to AU-rich elements in the 5’- and 3’- UTRs confers 
additional stability of the VEGF mRNA. Also the 5’ present IRES of the VEGF 
mRNA maintain efficient translation during stress conditions (Takahashi and 
Shibuya, 2005). 
VEGF-A binds two highly related receptor tyrosine kinases, VEGFR-1 and 
VEGFR-2. Another member of the VEGFR family is VEGFR-3, which binds 
VEGF-C and VEGF-D as ligands. The structure of these kinases 
encompasses seven extracellular Ig-like domains, a single transmembrane 
region and a tyrosine kinase sequence. Additionally, VEGF interacts with 
another family of coreceptors, the neuropilins (Ferrara, 2004). 
Although still controversial, VEGFR-1 probably functions as a decoy receptor, 
thereby preventing and fine tuning the VEGF response, especially the soluble 
form. Despite the higher binding affinity to VEGF in comparison to VEGFR-2, 
no ligand-induced mitogenic signalling and only weak autophosphorylation 
was detected. Nevertheless, the whole spectrum of functions of VEGFR-1, 
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like governing chemotaxis or migration, can differ due to the developmental 
stage and the cell type (Ferrara, 2004).  
 
 
Figure 3: VEGF isoforms and their interaction with VEGFRs  (Ferrara, 2004) 
 
Upon VEGF binding VEGFR-2 undergoes dimerization and tyrosine 
(auto)phosphorylation resulting in a mitogenic, chemotactic and prosurvival 
signal (Ferrara et al., 2003). Indeed, VEGF rescues endothelial cells from 
apoptosis during serum starvation (Byrne et al., 2005). Proteins activated by 
VEGF induced phosphorylation are phospholipase C-γ, PI-3 kinase, Ras 
GTPase-activating protein, src-family members or Raf (Zachary, 2003). 
VEGFR-2-/- mice die due to a lack of endothelial cell growth and blood vessel 
formation as well as extremely poor haematopoiesis (Takahashi and Shibuya, 
2005). Nowadays, there is general agreement that VEGFR-2 is the major 
mediator of the mitogenic, angiogenic and permeability-enhancing effects of 
VEGF (Ferrara, 2004).  
Albeit, VEGFR-2 is supported by a molecule, previously found to be involved 
in neuronal guidance, neuropilin (NP). NP1 binds VEGF, associates with 
VEGFR-2 and presents VEGF in a way that increases effectiveness of its 
mitogenic signalling (Ferrara, 2004). 
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Figure 4: Role of VEGFR tyrosine kinases in endothelial cells (Ferrara, 2004) 
I.5. DNA Microarray – VEGF versus EGF versus IL-1 
 
The expression profile of HUVEC induced by VEGF in comparison to the 
general growth factor EGF was analyzed with a microarray by Mag. Bernhard 
Schweighofer (Dep. Vascular Biology, Medical University of Vienna). HUVEC 
were stimulated with 100ng/ml medium VEGF165 and with 100ng/ml EGF at 
the time points 30 min, 60 min, 150 min and 360 min in order to monitor the 
early response to the angiogenic growth factor and dismantle potentially 
regulated genes relevant to sprouting and angiogenesis.  
Therefore, whole RNA was isolated from the induced cells and subjected to 
cRNA synthesis. The obtained cRNA was used as probes for a DNA 
Microarray (Affymetrix). Subsequently, the resulting expression rates were 
analyzed on a Microsoft Acces data sheet.   
A group of genes was found to be specifically upregulated by the angiogenic 
VEGF, but not by the general growth factor EGF. They were considered to be 
primarily relevant for angiogenesis. Furthermore, the microarray analysis 
included samples derived from HUVEC stimulated with the inflammatory 
cytokine interleukin-1. Thus, further dissection of genes regulated primarily 
during angiogenesis (VEGF), general growth (EGF) and inflammation (IL-1) 
was possible. In summary, from all 60 genes induced by VEGF around 20% 
were regulated by all three growth factors, 60% were stimulated by 
interleukin-1 and VEGF and about 20% of the genes were selectively 
regulated by VEGF alone (Schweighofer et al., 2007). 
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I.6. MEF2C: 
 
I.6.1 The pedigree of MEF2C: 
 
MEF2C (myocyte enhancing factor) is member of the MADS box containing 
transcriptions factor family (Gossett et al., 1989). The MADS box domain 
confers dimerization and DNA binding capability. This name is drawn from the 
four initially discovered transcription factors possessing this DNA binding 
domain: MCM1, Agamous, Deficiens and serum response factor. All MADS 
box transcription factors throughout all eukaryotic kingdoms have in common 
that they play a role in developmental processes. The animal and fungal 
MADS box transcription factors are subdivided into two categories: the SRF-
like and the MEF-like MADS box proteins (Messenguy and Dubois, 2003). 
The human MEF2 family comprises MEF2A, B, C and D. Adjacent to their 
very N- terminal MADS box they all share a highly homologous MEF2 motif; a 
region of 27 amino acids. This motif partly influences DNA binding affinity, 
indirectly dimerization and independently transcriptional activation. The C- 
terminus of MEF2 proteins confers transcriptional activity via two particular 
TADs (Trans Activation Domain) (Molkentin et al., 1996). MEF2 proteins bind 
the consensus sequence C/TTA(A/T)4TAG/A via the alpha helical part of the 
MADS box (Gossett et al., 1989). A contiguous beta- sheet mediates with its 
protruding hydrophobic interface dimerization to another MEF protein 
conferring DNA sequence specifity (Molkentin et al., 1996). 
A characteristic feature of MADS box proteins is their vast cooperation with a 
plethora of co-repressors and activators or transcription factors of other 
families (Messenguy and Dubois, 2003). 
Among the proteins reported to cooperate with MEF2C are: HDAC4, 5, 7, and 
9, MITR, Cabin and p300, MyoD, NFAT or ERK5 (Figure 5). 
This broad range of binding-partners accounts for the seemingly contradicting 
cellular processes MEF2C was shown to orchestrate. MEF2C regulates cell 
division, differentiation and death solely depending on the context or type of 
the cell (McKinsey et al., 2002). 
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Figure 5: Interaction partners of MEF2C (McKinsey et al., 2002) 
I.6.2. MEF2 regulation by HDACs: 
 
Chromatin histone modification is a widely accepted mode of transcriptional 
modification (Jenuwein and Allis, 2001). Accessibility of the promoter region 
for the transcription machinery vitally affects an expression rate of genes. 
Acetylations by HATs (Histone Acetyl Transferases) of positively charged 
lysines of histone proteins evoke repulsion of the negatively charged DNA. 
Consequently, local chromatin adopts a less constrained and therefore a 
more open conformation. However, when HDACs (HistoneDeACetylase) 
neutralize this transcription enhancing effect, chromatin becomes confined 
again and less accessible.  
All class II HDACs (HDAC4, 5, 7 and 9) were shown to constitutively 
associate via their N-terminus to DNA bound MEF2 (Chang et al., 2006; Wu 
et al., 2001). Thereby, they act as repressors on MEF2. 
For example, HDAC7 knockout mice reveal a disturbed vascular integrity. 
This is the result of the loss of MEF2C repression by HDAC7, because 
metalloproteinase 10 (MMP10) is a direct target of MEF2C and consequently 
becomes upregulated. This leads to an increased degradation of the ECM, 
thereby resulting in an interrupted vascular system (Chang et al., 2006). 
Furthermore, the existence of a negative- feedback loop involving HDAC9 and 
MEF2C was identified. The promoter of HDAC9 contains a MEF2 binding site 
whereby its own transcription is inhibited. During muscle differentiation this 
mechanism regulates gene expression by altering time course dependent 
expression levels (Haberland et al., 2007). 
The role of MEF2C in endothelial cells 
 15
I.6.3. Ca2+ dependent MEF2 regulation: 
 
The Ca2+ binding adaptor protein calmodulin is the central platform, where the 
different Ca2+ currents-triggered signalling pathways are integrated. Several 
anabranches of Ca2+ signalling contribute to MEF2 regulation at various levels 
in diverse forms. 
The Ca2+ /Calmodulin dependent kinase CaMKI’s capability to phosphorylate 
MEF2D could be demonstrated, but an active phosphorylation of MEF2A and 
C failed to be detected. However, CaMKI seems to influence MEF2C 
indirectly, because CaMKI dependent phosphorylation of HDACs disrupts the 
repressive HDAC-MEF2C interaction, as it creates a docking side for the 
chaperone 14-3-3 (McKinsey et al., 2002). Upon binding, a conformational 
change of the HADC demasks a NES (nuclear export signal) (Haberland et 
al., 2007). Moreover, MEF2C is thus accessible for the binding of the 
transcription enhancing factor HAT p300. Interestingly, p300 not only 
acetylates histones but MEF proteins as well, thereby auxiliary increasing 
their transcriptional activity (Ma et al., 2005). 
The Ca2+ /Calmodulin dependent phosphatase CaN (CalciNeurin) also has an 
impact on MEF2 signalling (McKinsey et al., 2002). Principally, one of the 
main targets of CaN is the transcription factor NFAT, which translocates into 
the nucleus upon dephosphorylation (Hogan et al., 2003). There, it is a 
potential coactivator of MEF2, binding cooperatively to a binding site 
proximate to the MEF2 consensus sequence. Thereby MEF2 activity 
increases. For MEF2D a further, protecting mechanism accomplished by the 
CaN was proposed. Hypophosphorylated MEF2D was less prone to caspase 
activity and subsequent proteolytic removal of MEF2D’s TAD (transactivation 
domain) (McKinsey et al., 2002). Whether this mechanism applies for all 
MEF2s and cell type remains unclear. 
The importance of Ca2+ signalling for MEF2C, at least in myocytes, 
demonstrates the finding of a positive feedback loop governed by the protein 
Calreticulin (Lynch et al., 2005). Calreticulin is a Ca2+ buffering protein, 
controlling its efflux from the endoplasmatic reticulum. It was shown, that CaN 
dependent dephosphorylation of MEF2C’s NLS containing C- terminus 
facilitates its nuclear import. The calreticulin gene is a direct target of MEF2C. 
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Thereby, a constant supply of Ca2+ and subsequently nuclear MEF2C is 
maintained.  
I.6.4. MAPK dependent MEF2 regulation: 
 
The MAPKs (Mitogen- Activated Protein Kinsases) are a family of serine/ 
threonine kinases that play an essential role in signal transduction by 
modulating gene transcription in response to changes in the cellular 
environment. They include the extracellular signal-regulated protein kinases 
ERK1 and ERK2, the c-Jun N- terminal kinases JNK1-3, p38 and ERK5 
(Turjanski et al., 2007). All MAPKs were shown to interact with MEF2C under 
a range of circumstances. 
 
p38 is the mammalian orthologoue of the yeast HOG Kinase, a cell stress 
sensor (Ren et al., 2007). Han et al. found MEF2C to be specifically 
phosphorylated by p38 upon LPS stimulation of monocytes, demonstrating 
MEF2C is involved in pro-inflammatory processes in leukocytes (Han et al., 
1997). Also in B-cells MEF2C is expressed (Swanson et al., 1998), whereas 
in T-cells MEF2D plays a regulatory role stimulated by Ca2+ signalling 
enhanced by p300 (Youn et al., 2000). In cardiac myocytes the p38/MEF2C 
pathway is induced by all-trans retinoic acids, thereby stimulating 
developmental processes in the embryonic heart (Ren et al., 2007). These 
findings stand in one line with other investigations, suggesting MEF2C is a 
key regulator of myocardial development. Additionally for example, it was 
demonstrated, that ROS-induced cardiovascular differentiation via the 
p38/MEF2C pathway. This study suggested that the p38/MEF2C pathway is 
involved in cardiogenesis but not in angiogenesis (Schmelter et al., 2006). 
 
ERK5 was shown to be responsive to stimuli and to regulate early gene 
expression through MEF2C (Kato et al., 1997). The structure of ERK5 is 
unique and permits distinct biological functions and mechanisms of regulation. 
Aside from its kinase activity ERK5 possesses an additional domain, which is 
capable to recruit the transcription machinery. Thereby ERK5 enhances 
MEF2C activity in a dual manner. Because of this extra domain, the size of 
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ERK5 is considerably increased, hence the synonym big MAP kinase 1 
(BMK1) (Kato et al., 2000). 
BMK1 knock-out-mice phenotype resembles the MEF2C knock- out 
phenotype. It causes embryonic death at day E9.5- 10.5, displaying severe 
defects during cardio- and vasculogenesis (Hayashi and Lee, 2004). Ablation 
in an inducible BMK1 knock-out- mouse leads to lethality within two to four 
weeks and to all signs of perturbed vascular integrity (abnormally leaky blood 
vessels, haemorrhages in multiple organs, lining vessels became round and 
irregularly aligned and apoptotic). Surprisingly, mice with a conditional knock 
out in smooth muscle cells remained viable to term. In contrast, conditional 
BMK1 knock- out- mice in endothelial cells show an indistinguishable 
phenotype to the global knock- out. Interestingly, in vitro a constitutively active 
form of MEF2C partially rescued the BMK1 knock- out phenotype (Hayashi et 
al., 2004). This undermines the hypothesis serum or VEGF induced ERK5/ 
BMK1 mediates pro- survival cell signalling in endothelial cells via MEF2C 
(Olson, 2004). 
 
I.6.5. Posttranslational modifications: 
 
The functional mode of a transcription factor is regulated by posttranslational 
modifications of the protein. In summary, MEF2C was reported to be 
phosphorylated, acetylated, sumoylated and ubiquitinated. Phosphorylation 
has been shown to alter the function of MEF2C. For example, p38 (Thr293, 
Thr300 and Ser387) or ERK5 (Ser387) mediated phosphorylation was shown 
to be activating (Kato et al., 1997; Ren et al., 2007) whereas other 
phosporylations (Ser396) probably mediated by CDK1 kinase seemed to 
facilitate sumoylation and consequently inhibition of MEF2C (Kang et al., 
2006). Additionally, association of MEF2C with class II HDACs potentiated 
sumoylation of MEF2C, which further regulates MEF2C negatively (Gregoire 
and Yang, 2005). Acetylation was proved to enhance DNA binding and 
therefore activate transcription (Ma et al., 2005). Nevertheless, ubiquitination 
of MEF2C seems to be part of the normal metabolic protein turn-over.  
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I.6.6. MEF2C cell expression pattern: 
 
Generally, the effects of MEF2C’s signalling depend on the cellular context. 
During embryogenesis MEF2C is the first of the four MEF2 family members to 
be expressed and here especially in embryonic muscle cells. As MEF2C has 
long been proven to be the key regulator of muscle differentiation, most 
investigations are focused on muscle cells (Olson et al., 1995). Because of 
the missing heart morphogenesis in MEF2C null mice, researchers expect to 
gain insights into pathologies like heart failure when elucidating mechanisms 
in cardiomyocytes involving MEF2C.  
Nevertheless, MEF2C is also highly expressed in the human brain during fetal 
development (Leifer et al., 1994). Only recently, data on the role of MEF2C 
during neurogenesis emerge. Remarkably, there seem to be parallels 
between regulation of muscle and neuron development, merely differing in the 
specific targets reached by MEF2C (Shalizi and Bonni, 2005). 
A minor requirement for MEF2C is exhibited by leucocytes (Swanson et al., 
1998) and chondrocytes. It exerts again developmental functions in these 
cells. Monocytes become further activated by a pro-inflammatory stimulus 
through MEF2C (Han et al., 1997). In chondrocytes MEF2C, regulated by 
HDAC4, controls the programme for hypertrophy and accurate bone 
development (Arnold et al., 2007). 
 
I.6.7. MEF2C in angiogenesis: 
 
In regard of angiogenesis and endothelial cell differentiation and function 
results from the MEF2C knockout mouse are very promising.  
The first null MEF2C mutant mice were created by targeted deletion of the 
MADS- and MEF-domains. No homozygous neonates were obtained, 
although the heterozygotes did not show a discernible phenotype. The 
embryos succumbed at day 9.5 to 10.5 postcoitum for which primarily the 
obviously severe heart phenotype resulting from aberrant cardiac 
morphogenesis was held responsible (Lin et al., 1997). Additionally, intricate 
vascular defects occurred. Organisation of endothelial cells into an ordered 
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pattern of a vascular plexus failed as well as recruitment and differentiation of 
smooth muscle cells, a characteristic step during late angiogenesis.  All these 
pathological appearances are reminiscent of VEGF-A mutant mice as well as 
VEGF receptor-2 defective models, implicating a likely association between 
VEGF and MEF2C signalling in endothelial cells during vasculo- and 
angiogenesis (Lin et al., 1998).  
Bi et al dissected the vascular phenotype of MEF2C-null mice to even more 
detail: they describe vascular malformations including the arrest of yolk sac 
vascular development as a capillary structure and its vessels’ rupture, vessels 
were enlarged, but exhibited a simpler branching whereas veins were 
constricted and endothelial cells were of round shape and abnormal 
orientation (Bi et al., 1999). Remarkably, expression patterns were altered 
particularly in cardiac cells, showing a reduced expression of Ang1 and 
VEGF, again connecting MEF2C signalling with VEGF in a vascular 
development background (Bi et al., 1999). 
The group of Jeffrey Molkentin struggled to obtain MEF2 overexpressing 
transgenic mice, but unfortunately, they only acquired MEF2A transgenics. 
The only viable offspring of the MEF2C transgenic line showed a detectable 
MEF2C overexpression of only 1.6-fold, indicating a barely tolerable impact of 
the overexpression on the animals’ homoeostasis (Xu et al., 2006). On 
cellular level, overexpression of MEF2C by adenovirus in cardiomyocytes 
revealed upregulation of three functional groups of genes detected on a 
microarray. These groups include metabolism related genes, genes involved 
in remodelling of the ECM and genes concerned with ion handling (Xu et al., 
2006). All these genes could also play a reasonable role in the process of 
angiogenesis. 
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I.7. Adenovirus: 
 
For the purpose of gene delivery into a cell several ways can be chosen. On 
the one hand DNA might be transfected into a cell by means of chemical 
manipulation like PEI mediated transfection. On the other hand a vector-
containing virus like adeno- or retroviruses might carry a gene of interest into 
a cell. It is also endeavoured to optimize adenoviruses in a way that they can 
be administered to patients as gene therapy. Cancer could be treated by gene 
therapy by introducing a growth inhibiting gene for example (Yang et al., 
2007).  
Concerning laboratory use, transfections are comparably easily accomplished 
considering expenditure of time to prepare a suitable expression vector as 
well as the relatively cheap reagents, but for HUVECs efficiency ranges only 
from 30-50%, which is too less for physiological assays. Additionally, the 
chemical manipulation of the cells harms their integrity, which is 
counterproductive for testing physiologic cell behaviour such as angiogenesis 
assays.  
Hence, for the purpose of angiogenesis assays the adoption of an adenoviral 
vector to introduce a gene of interest into cells seems reasonable; a suitable 
multiplicity of infection warrants 100% target gene delivery efficiency and the 
cells are not physically harmed by the replication-deficient Adenovirus. 
Adenoviruses are non-enveloped linear DNA- viruses. 49 subtypes subdivided 
into 6 subgroups are described. In humans they can cause respiratory, 
gastrointestinal and ocular diseases. Commonly, adenoviruses of type 2 and 
5 are employed in molecularbiology. Principally, adenoviruses code for five 
early (E1A-E4), two intermediate and five late transcription elements. The 
latter are encoding structural proteins for the capsid. Inverted Terminal 
Repeats (ITRs) positioned at the viral chromosome’s end serve as replication 
origins. E1A+B are necessary for starting the replication of the viral 
chromosome and have cell transforming properties. Therefore, E1 deficient 
viruses are rendered replication deficient. These viruses can be propagated in 
E1-transcomplementing cell lines. Consequently, deletion of these genes 
provides space for inserting a gene-of-interest as well as it prevents 
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unintentional, potentially harmful virus propagation outside of complementing 
cell lines. 
A further benefit of adenoviruses encompasses their capability of infecting 
non-dividing as well as dividing cells. The classical way of invasion into a cell 
for adenoviruses proceeds via the CAR receptor. The size of the obtained, 
available cloning space of adenoviral vectors arises from the elimination but 
trans-complementation of the E1/E3 genes and from the fact, that it tolerates 
105% of the natural viral genome packaging.  Altogether 8.1–8.2 kb are the 
size limit for the introduced foreign fragment. Finally, it is noteworthy, that the 
viral genome remains episomal in contrast to for example retroviruses. 
Therefore, undesirable recombination events do not take place (Mizuguchi et 
al., 2001). 
Several different methods to generate recombinant adenoviruses were 
established and optimized during the last decades. First, there is the in vitro 
ligation method, where the gene of interest is ligated to the adenoviral DNA 
and transfected into 293 cells. Second, there is the homologous 
recombination method in 293 cells. A plasmid encoding the gene of interest 
and a plasmid harbouring the adenoviral genome are co-transfected into 293 
cells, which are supposed to recombine at the ITRs, but these events occur 
very rarely in mammalian cells and often randomly. Third, a continuation of 
the recombination idea is the homologous recombination method in bacteria. 
The bacterial homologous recombination system is highly efficient and 
reliable. Additionally, the co-transformation efficiency of the two plasmids into 
bacteria is very high. One plasmid contains the gene of interest under the 
control of a suitable promoter and optionally a reporter gene. The other 
plasmid encodes the adenoviral backbone. Several companies provide a kit 
for this method; for example the AdEasy™ Adenoviral Vector System kit from 
Stratagene®, which is explained to further detail in Materials&Methods. 
Subsequently, the large scale amplification of the recombinant virus becomes 
necessary for efficient use in angiogenesis assays. Here, purification of the 
viral particles is the crucial step. On the one hand abundant loss of viral 
particles has to be avoided and on the other hand, one has to be aware, that 
not all produced particles are viable and functional. The last question can be 
addressed by a titre determination, because only viable particles are 
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infectious. Titres can be tested with antibody- based staining kits. For the viral 
particle purification from a vast amount of cell lysate still the established 
technique of caesium chloride density centrifugation with subsequent glycerol 
buffer dialysis seems to be the method of choice. Alternatively, newly 
developed filtering kits based on chromatographically separation of the 
particles are available. Moreover, caesium chloride density centrifugation is 
even capable to separate complete particles from incomplete like empty 
capsids, aberrant particles or clustered junk material when adequately 
equipped centrifuges are available (Berkowitz and Philo, 2007; Mizuguchi et 
al., 2001).  
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II. Materials and Methods: 
 
II.1. Vectors and Plasmids: 
 
The cDNA of the gene of interest (MEF2C) was cloned in the high-copy 
plasmid pBluescriptR. For expression in mammalian cells and in order of 
adenovirus production MEF2C was subcloned into the pShuttle-IRES-hrGFP-
1 Vector, containing a CMV promoter and recombination sites homolog to the 
recombination sites in the pAdEasy vector, which was providing the 
adenoviral construct, resulting in a MEF2C expressing adenovirus after 
bacterial recombination subsequent to cotransfection into E.coli.  
 
 
Plasmid/ Vector Application Source Size  
pBluescriptR- 
IRATp970F1023D 
Full length cDNA clone of MEF2C 
(ampR) 
RZPD 4.1 kb 
pShuttle-IRES-
hrGFP-1 
Shuttle vector for bacterial 
recombination for adenovirus 
production; CMV promoter containing 
expression vector for mammalian 
cells (kanR) 
Stratagene 8.9 kb 
pAdEasy-1 
E1/E3 deleted adenoviral backbone 
containing vector for bacterial 
recombination for adenovirus 
production 
Stratagene 33.5kb
 
The restriction maps of the vectors are shown in the appendix. 
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II.2. Primers: 
 
For Primer design see II.2.3.5. All primers were purchased from Invitrogen. 
Gene 
Sequence 
(5’-NNN-3’) 
Application 
pShuttle-IRES-hrGFP1_fw ctcacggggatttccaagtc sequencing 
pShuttle-IRES-hrGFP1_rev atgcagtcgaggaattg sequencing 
MEF2C_472-446 cgaggattatggatgaacgt sequencing 
MEF2C_1078-1097 tggtctcacctggtaacttg sequencing 
M13 fw 18-mer tgtaaaacgacggccagt sequencing 
M13 rev 17-mer caggaaacagctatgac sequencing 
MEF2A_fw ccgactgcctacaacactga realtime PCR 
MEF2A_rev cctgagataactgccctcca realtime PCR 
SELE_fw ggaagctaccaaaagccttc realtime PCR 
SELE_rev ccagagacccgaggagagtt realtime PCR 
MEF2C_fw catccactgccaccatctgc realtime PCR 
MEF2C_rev cgtgtgttgtgggtatctcg realtime PCR 
EGR3_fw* gacaatctgtaccccgagga realtime PCR 
EGR3_rev* tccaagtaggtcaggtct realtime PCR 
DSCR1_fw* tagctccctgattgcctgt realtime PCR 
DSCR1_rev* ggagaaggggttgctgaagt realtime PCR 
NR4A2_fw* tttctgccttctcctgcatt realtime PCR 
NR4A2_rev* gtggcaccaagtcttccaat realtime PCR 
HLX1_fw* ctccaacctgcagaggaaag realtime PCR 
HLX1_rev* ggttctggaaccacaccttc realtime PCR 
MEF2C_endogen_fw   ggcagaagccaagagacctt realtime PCR 
MEF2C_endogen_rev  aggcaggctagcatccttta realtime PCR 
MMP10_fw tgagcctaaggttgatgctg realtime PCR 
MMP10_rev ccctatctcgcctagcaatg realtime PCR 
ß2M_fw gatgagtatgcctgccgtgtg realtime PCR 
ß2M_rev caatccaaatgcggcatct realtime PCR 
 
* Asterix marked primers were kindly provided from Mag. Bernhard Schweighofer 
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II.3. Restriction endonucleases and DNA modifying enzymes: 
 
For subcloning of the fragment coding for MEF2C the pIRAT plasmid and 
pShuttle-IRES-hrGFP-1 were cut with NotI and SpeI (Roche).  
T4 DNA Ligase (New England Biolabs) was employed for sticky end ligation. 
For sequencing PCR fragment amplifaction was performed with Pfu 
polymerase (Biotherm).  
Linearization of the pShuttle-IRES-hrGFP-1 vector was done with PmeI (New 
England Biolabs).  
Subsequent dephosphorylation was conducted with alkaline Phosphatase 
(Roche).  
Control restriction of positive recombination after cotransfection was 
performed with PacI. (Roche) 
 
II.4. Antibodies (Western blot): 
 
Application Name Source 
Primary Antibody goat-anti-MEF2C Santa Cruz Biotechnologies 
Secondary Antibody HRP-donkey-anti-goat-IgG Santa Cruz Biotechnologies 
development 
reagents Lumiglo+ peroxide 
 Cell Signalling 
Biotechnologies 
 
 
II.5. Cells: 
 
II.5.1 HUVEC: 
 
HUVECs are human umbilical vein endothelial cells, directly extracted from 
umbilical cords after collagenase treatment. They are biosafety level 1, 
primary cells, usually used up to passage number 6. Splitting in a ratio of 1:3 
or medium change every two to three days is recommendable. They are 
adherent cells and require 1% gelatine coated culture vessels.  
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HUVEC are kept in M199 medium (Lonza), completed with 20% EC-FCS 
(endothelial fetal calf serum), 1% antibiotic mix (Penicillin, Streptomycin, 
Funghizon and Glutamin), 0.4% ECGS (endothelial growth supplement) and 
0.026% heparin to prevent fibroblasts growth and sterile filtered through a 
0.2µm pore membrane (Milipore) at 37° and 5% CO2. Protocol for 
subculturing is  
• Remove and discard old culture medium.  
• Briefly rinse the cell layer with 1x PBS solution to remove all traces of 
serum which contains trypsin inhibitor.  
• Add 3.0 ml of Trypsin-EDTA solution to a 175 cm² flask and observe 
cells under an inverted microscope until cell layer is dispersed (usually 
within 5 to 15 minutes). 
• (Cells that are difficult to detach may be placed at 37°C to facilitate 
dispersal.) 
• Add 9 ml of complete growth medium and aspirate cells by gently 
pipetting.  
• Add appropriate aliquots of the cell suspension to freshly coated new 
culture vessels and fill up with complete medium to 25ml.   
For stimulation with growth factors HUVEC were serum starved meaning not 
fed for 3 days.  
100ng VEGF- A165, bFGF and IL1 and 25ng EGF diluted in serum- free 
medium were added to the starved HUVEC cells of a 6- well covered with 
exactly 1ml medium.  
 
II.5.2 293 cells: 
 
293 cells are human embryonic kidney (epithelium) cells. They originate from 
a cell line. Immortalization was obtained by transformation with Adenovirus 5. 
An insert consisting of ~4.5 kilobases from the left arm of the viral genome 
became incorporated into human chromosome 19, rendering them also useful 
for adenoviral titration.  
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293 cells are maintained in Mem-alpha medium (Invitrogen), supplemented 
with 10% NCS (neonatal calf serum), 1% Penicillin/ Streptomycin mix and 1% 
L-Glutamin (200mM) and sterile filtered.  
They do not urgently need gelatinized plates but coating supports their 
accommodation. 293 cells should not be grown to full density to prevent 
dividing stop, can be splitted in ratios 1:4 up to 1:10 and are used up to 
passage number 25. For subculturing the protocol for HUVECs applies 
likewise. (see II.1.5.1.) 
 
II.6. Bacterial Cultures: 
 
All E. coli strains (DH10B, XL Gold and BJ5183 Rec+) used were grown in LB 
(Luria- Broth) medium and plated on selective agarose dishes.  
Therefore, a ready-to-use LB medium mix (Invitrogen) containing 1% Trypton, 
0.5% yeast extract and 1% NaCl was solved in bidest water and autoclaved 
for sterilization.  
Antibiotic stocks were prepared with concentrations of 50 mg/ml of Ampicillin 
in water and 10 mg/ml of Kanamycin in water. For selective plates final 
working concentrations were 50µg/ml antibiotics in LB medium.  
Principally, for the preparation of bacteria culture plates, 4 g Bacto-Agar 
(BectonDickinson) added to 200 ml sterile LB medium were heated until the 
solution was homogenous and solved completely. After subsequent cooling 
down to ~50°C, antibiotics stocks were added in adjusting concentrations. 
Immediately afterwards, the LB- Agarose solution was casted into 
approximately ten to fifteen round dishes (10cm), allowed to solidify and 
eventually stored at 4°C.  
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II.7. Agarose gel electrophoresis: 
 
For separation of DNA fragments agarose gel electrophoresis was performed 
with 1% agarose gels for fragments up to 15 kb or 0.8% agarose gels for 
fragments >15 kb using a multipurpose agarose (Roche). For preparative 
DNA separation a low-melting agarose was employed to obviate potential 
enzyme- inhibitive contamination with agarose of subsequently extracted 
DNA.  
Principally, agarose was added to 30 ml of 1x TAE buffer and the solution was 
heated in the microwave ensuring complete resolving of the agarose. 
Subsequent to cooling, 1µl of ethidium bromide solution, which is very 
carcinogenic and tends to sublimate, was added. Finally, the gel was casted 
into the chamber followed by insertion of the comb of size, appropriate for the 
amount of DNA desired to be loaded.  
After polymerization of the gel, samples were mixed with a 6x loading buffer 
(fermentas) and loaded into the gel slots. Additionally, to enable determination 
of the DNA fragment size either a 1kb, a 123bp or a lambda DNA BstII ladder 
(fermentas) was loaded as a marker. The gel ran at 70 to 80 Volts in the 1x 
TAE buffer filled chamber for approximately 45 minutes or until the marker 
was separated satisfyingly.  
 
II.8. Protein analysis: 
 
II.8.1. SDS- Polyacrylamid Gel separation: 
 
For electrophoresis the PeqLab system was used. A standard gel was set up 
employing either 0,75mm or 1,5mm spacers, a 12 teeth comb and 10x10cm 
glass plates. The protein MEF2C has 44kDa and therefore a 12% resolving 
gel was prepared.  
1.6ml dH2O, 2ml acrylamide mix, 1.3ml 1.5M Tris (pH 8.8), 50µl 10%SDS, 
50µl freshly prepared 10% APS and 2µl TEMED are mixed in a disposable 
tube, poured into the ready assembled casting frame and allowed to 
polymerize. To ensure an even gel edge the mixture was overlayed with 
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isopropanol. After polymerization, the isopropanol was removed thoroughly. 
For a 5% stacking gel 2.1ml dH2O, 0.5ml 30% acrylamide mix, 0.38ml 1M Tris 
(pH 6.8), 30µl 10% SDS, 30µl 10% APS and 3µl TEMED were mixed and 
filled onto the top of the resolving gel. The comb was inserted instantly to 
ensure a regular polymerization. It was crucial to avoid air bubbles to warrant 
an uninterrupted sample run. After polymerization the comb was removed and 
the slots were washed with electrophoresis buffer (25mM Tris, 250mM glycine 
and 0.1% SDS).  
Samples were resolved in 100µl/ 6-well cells sample- “Lämmli”- buffer 
(0.0625M Tris (pH 6.8), 10% glycerol, 2%SDS, 5% mercaptoethanol, 0.05% 
bromphenolblue in water). Previous to loading they were heated at 95°C for 
10 minutes. Samples were loaded into the slots with loading tips as well as 
the prestained protein marker (fermentas). The tank was filled up with 
electrophoresis buffer. For power supply the 500/ 1000 Biorad power supplier 
was used. The gel was run at 150V and 20mA until loading buffer front 
reached the bottom. 
 
II.8.2. Western blot: 
 
Immuno-blotting using the semi-dry blotter from PeqLab followed.  
Thus, 3mm Whatman Paper and the PVDF membrane (Millipore) were cut to 
the right size. The membrane was soaked in methanol for 15 seconds, in 
water for 2 minutes and in blotting buffer (25mM Tris, 192 mM glycine and 
20% methanol) for 2 minutes. The Whatman Paper was soaked in blotting 
buffer. The blotting sandwich was built up starting from bottom with 3 pieces 
Whatman Paper, the membrane, the gel and finally 3 pieces Whatman Paper 
again on the top. To ascertain unhindered current flow air, bubbles within the 
sandwich were removed and the lower blotter plate was dried around the 
sandwich area. The top cover of the semi-dry blotter should not be closed too 
tightly to avoid drying of the gel. For power supply the 200/0.2 Biorad supplier 
was employed. In case of one small gel, blotting was allowed for 1 hour at 
maximally 200mA according to the manuals. 
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II.8.3 Evaluation of Blot: 
 
After blotting, the membrane was removed, washed in methanol and left in the 
flue to dry completely. Afterwards, the membrane was blocked with 3ml 
5%BSA in 0.1%Tween 20 in PBS for 30 minutes. Subsequently, the first 
antibody was added in recommended concentration and allowed to bind at 
4°C overnight. The membrane was washed three times for 5 minutes with 
0.1% Tween 20 in PBS. Incubation for one hour at room-temperature with 
HRP-conjugated second antibody followed. Finally, the membrane was 
washed again three times for 5 minutes with 0.1% Tween 20 in PBS. 
Afterwards, the membrane was incubated with 125µl solution A and 125µl 
solution B (Cell Signalling) diluted with 2.25ml dH2O. After one minute a film 
(Kodiak) was exposed to the membrane and succeedingly developed in the 
machine Curix60/ Agfa.  
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II.9. Real Time Reverse Transcription Polymerase Chain Reaction: 
 
II.9.1. Total RNA Isolation: 
 
Prerequisite for isolating total RNA is to work with adequate material. This 
includes RNAse- free pipettes washed with RNAaway, aerosol resistant tips 
and solutions, like sterile or DEPC treated water.  
Cells were fixed with 300µl/ 6- well RNAlater (Ambion) for 1 minute, washed 
with 1ml/ 6-well sterile water and lysed with 1ml/ 6-well TRIzol (Invitrogen). 
The thoroughly mashed cell-lysate was transferred to a prepared 1.5ml 
reaction tube. At this point, the resuspension might either be stored at –20°C 
or incubated at room- temperature for 5 minutes. 
Succeeding, 200µl chloroform were added, mixed intensely for 15 seconds 
and subsequently incubated for 2-3 minutes, followed by centrifugation for 15 
minutes at maximum speed. RNA should only be in the aqueous, top phase 
and transferred to a new reaction tube. Attention should be paid, not to touch 
the intermediated phase. 500µl isopropanol were added, mixed, incubated for 
10 minutes at RT and centrifuged for 10 minutes at 12000g. The pelleted RNA 
was washed twice with ice- cold 75% RNAse free Ethanol. The RNA was 
dissolved in 22µl DEPC treated water (Invitrogen) and incubated at 55°C for 5 
minutes. 
 
II.9.2. cDNA Synthesis: 
 
For a preparation of 20µl total 10µl of the obtained RNA Isolation, 1µl 
Oligo(dT)12-18 (500µg/ml; Invitrogen) and 1µl dNTP Mix (10mM; Invitrogen) 
were incubated at 65°C for 5 minutes, cooled on ice and spinned down and 
complemented with 4µl 5x FirstStrandBuffer, 2µl DDT (100mM) and 1µl 
RNAse OUT (40U/µl) (Invitrogen), mixed and incubated at 42°C for 2 minutes. 
Finally 1µl Superscript enzyme (Invitrogen) was added.   
Superscript was allowed to work for 50 minutes at 42°C and inactivated for 15 
minutes at 70°C.  
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II.9.4. Quantitative Real Time PCR: 
 
The obtained cDNA had to be diluted with 30µl water.  
Initially, the Light Cylcler Mastermix (enzyme and cybergreen) was prepared 
according to the manufactor’s instructions (Le Roche). For a total of 10µl 1µl 
cDNA, 1µl of each 5mM Primer (see design), 1µl Light Cylcer mastermix and 
6µl water were mixed. This is a quantitative analysis. Therefore precise 
pipettes had to be used. The reaction mix is light sensitive. Therefore it 
demanded diligent pipetting and reaction tubes were kept cooled and light 
protected. The reaction mix was transferred to according capillaries and these 
were inserted into the light cycler in correct order.  
 
The amplification and detection process ran on the following conditions: 
Temperature Hold time 
Denaturation Cycles: 1 
95°C 600 sec 
Amplification Cycles: 54 
95°C 5 sec 
63°C (dep. on primer) 5 sec 
72°C 15 sec 
Melting Cycles: 1 
95°C 10 sec 
70°C 30 sec 
95°C 0 sec 
Cooling Cycles: 1 
40°C 10 sec 
 
 
Recording of the results is automated. When PCR reaction was finished 
melting curves were examined on the computer for the correct course of 
action.  
Examples for amplification and melting curves for the gene MEF2C are shown 
in the appendix. 
 
To calculate the fold induction values of unstimulated control cells the means 
of the turning points (cycles) for ß2Microglobulin and the analysed gene of the 
unstimulated control cells had to be determined beforehand. The fold 
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induction normalized with ß2Microglobulin was calculated with the following 
formula: 
 
F= a (Mx – x) * b (y – My)  
 
“F” is the result of the calculated fold induction based on the values obtained 
from the control cells. “a” and “b” describe the efficiency of the employed 
primers for the tested gene and the internal standard ß2Microglobulin 
respectively. The efficiency of the ß2Microglobulin primers was presumed to 
be 2.2 and the efficiency of the primers for the tested gene was presumed to 
be 2. “Mx” represents the mean value of the turning points of the analysed 
gene of the unstimulated cells and “x” is a particular value of turning point of 
the tested gene. Similarly, “My” represents the mean value of the turning 
points of ß2Microglobulin (internal standard) of the unstimulated cells and “y” 
is a particular value of turning point of the internal standard. Afterwards, the 
mean value and the resulting standard deviations of the calculated fold 
induction of three samples were determined.  
II.9.5. Primer design: 
 
Primers were designed with the program “Prime3”. For light cycling PCR 
primers had to meet certain demands. The PCR product must not be longer 
than 200bp, ideally 100- 150bp. The amplified sequence should include an 
intron- exon- border to ensure the amplification of cDNA instead of an 
eventual chromosomal DNA contamination. Additionally, 3’ end seated 
sequences should be preferred, because it may happen that mRNA 
transcription by Superscript was incomplete. 
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II.10. Plasmid DNA assignments:  
 
For plasmid DNA amplification plasmids are transfected into either chemical 
or electro competent E.coli.  
Standard procedure steps of transfecting chemical competent cells are 
thawing of a 100µl aliquot of bacteria on ice, addition of 0.2µg DNA in 1µl 
dH2O and incubation for 20 minutes on ice, transfer into a 14 ml cooled, round 
bottom tube, heat shock at 42°C for 40 seconds, instant reanimation with 1ml 
37°C prewarmed LB medium and shaking for one hour at 37°C at 200rpm. 
Aliquots are plated on selective plates and incubated at 37° overnight 
subsequently. 
 
When higher transfection efficiency was needed or when two plasmids had to 
be cotransfected, electro competent bacteria were used. For transfection of 
electro competent E.coli, electroporation cuvettes were prechilled. Vials with 
40µl aliquots of electro-competent cells were allowed to thaw on ice. They 
were gently mixed with the added 1µg/µl DNA. Amount of water and salt 
purity of the sample are critical in this procedure. The bacteria were 
transferred to the ice-cold cuvette, which was inserted into the electroporator. 
(BioRad) The parameter adjustment for an electroporation impulse of bacteria 
was 2.1 kV, 25 µF, 200Ω and 4.2 milliseconds. Afterwards, cells were 
reanimated immediately with 400µl prewarmed LB medium (37°C). The cells 
were incubated at 37°C and 200rpm for one hour. Subsequently, they were 
plated on selective LB plates and incubated at 37° overnight. 
 
Positively resistant colonies were picked under sterile conditions, inoculated 
into 5ml LB media and incubated at 37° overnight. This was used as either a 
starting culture for large scale amplification in 300ml LB media, which was 
incubated overnight again, or for plasmid preparation employing the Mini 
Plasmid Purification kit (Qiagen) subsequent to 15 minutes centrifugation at 
3000 rpm. Hereby obtained DNA was eluted with 50- 100µl dH2O. 
Concentration and protein contamination purity was measured with the UV/ 
visible Spectrophotometer (Pharmacia Biotechnologies) at 260 nm/ 280 nm.  
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The Midi Plasmid Purification kit (Qiagen) was used to acquire a higher 
amount of DNA out of the obtained 300ml bacteria suspension.  
To ensure whether the correct plasmid has been amplified, a small DNA 
aliquot was subjected to restriction enzyme digestion and subsequent 1% 
agarose DNA separation showing potentially appropriate fragments.  
For directed DNA cutting restriction enzymes are employed.  
Considerations about special requests of an enzyme regarding optimal 
working temperature and particularly buffer conditions are important when two 
different enzymes are used for a double digestion. In a standard course of 
action a 10 fold excess of enzyme activity is prepared, meaning for 1µg DNA 
to be digested, 10 Units enzyme are added. 
Double digestion preparations of pBluescriptR-IRATp970F1023D and 
pShuttle-IRES-hrGFP-1 plasmids with NotI and SpeI serve as an example: 
 
4µl pBluescriptR-MEF2C  (0.5µg/ µl) 
1µl 10x buffer H (Roche) 
1µl dH2O 
4µl SpeI (10U/ µl) (Roche) 
or 
4µl NotI (10U/ µl) (Roche) 
Total: 10µl at 37°C for 90 minutes 
(2 times) 
1µl pShuttle-IRES-hrGFP-1 (1µg/ µl) 
1µl 10x buffer H (Roche) 
7µl dH2O 
1µl SpeI (10U/ µl) (Roche) 
or 
1µl NotI (10U/ µl) (Roche) 
Total: 10µl at 37°C for 90 minutes 
(2 times) 
 
The first digestion was controlled on an agarose gel to ascertain a complete 
digestion. Save of that, the reciprocal enzyme was added and incubated for 90 
minutes at 37°C again.  
 
In order to obtain a plasmid fragment supposed to be subcloned, the whole volume of 
the enzyme digestion preparation was loaded onto a 1% low-melt agarose gel and 
separated. Under UV light the desired fragment of the right size was cut out of the gel 
with a scalpel. DNA was retrieved from the agarose piece with the Gel Purification 
kit (Qiagen) and eluted with water. This kit can also be used as an Enzyme Reaction 
Purification kit. 
 
To reassemble the fragment and the target plasmid or any cut DNA pieces a T4 
ligase mediated ligation was performed. Crucial for this reaction was the molar insert 
to vector ratio, which should range from 1:4 to 1:10. Total amount of DNA is (as in all 
enzyme reactions) also critical. 
Ligation of the MEF2C cDNA containing fragment and pShuttle-IRES-hrGFP-1 vetcor 
serve as an example.  
 
0.5µl pShuttle-IRES-hrGFP-1 (100ng DNA)                        
2µl insert (225ng DNA) 
1µl ATP (10mM) (Invitrogen) 
1µl 10x buffer 
1µl T4 Ligase (400U/ µl) (Fermentas) 
Total: 10µl at 16°C overnight  
 
1µl of the ligation had to be retransformed into chemical competent cells. DNA from 
positive colonies on the according selective plate was tested by enzyme restriction 
and control agarose gel separation to possess the correct fragment insertion.  
 
To prevent religation and to ensure persistent linearization of a cut vector, DNA was 
subjected to alkaline Phosphatase (1U/ µl) (Roche) in supplemented 10x buffer at 
37°C for 60 minutes; 1 unit alkaline phosphatase dephosphorylates 1pmol DNA in 60 
minutes at 37°C.  
 
1: 9 molar ratio 
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For exact single base pair verification of DNA samples, sequencing was necessary. 
Therefore, Ethanol precipitated DNA (+ 1/10x Volume NaAcetat pH 5.2, + 2.5x 
Volume 100% EtOH for 20 minutes at RT and 25 minutes centrifugation at maximum 
speed at 4°C) was sent to the company MWG biotechnologies. Standard primers 
were provided and individual primers had to be delivered. Transmitted sequence was 
analyzed with the programme McVector.  
 
For sequencing of a small fragment of a large vector or any reliable qualitative 
amplification, the fragment had to be amplified by PCR using Pfu polymerase, which 
contains a proofreading function.   
 
32µ dH2O 
2µl DNA 
5µl Primer (10nM) forward 
5µ Primer (10nM) reverse 
5µl 10x buffer 
0.5µl dNTPs (10mM) (Invitrogen) 
0.5 µl Pfu Polymerase 
Total: 50µl for touch down PCR schedule 
 
PCR program ran on PerkinElmer machine: 
Time   Temperature 
3’         94°C 
30’’      94°C 
30’’      65°C               35 cycles, -0.3°C 
3’30’’   72°C 
7’         72°C 
             4°C 
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II.11. Production of a recombinant adenovirus: 
 
Recombinant adenovirus was produced with the help of the AdEasy™ Adenoviral 
Vector System kit from Stratagene®.  
Here, the gene of interest is cloned into the supplied “shuttle vector” into its MCS 
under the control of a CMV promoter and a SV40- polyadenylation site. This plasmid 
pShuttle-IRES-hrGFP-1 also encodes a humanized GPF protein driven by an IRES 
element and provides the option of a 3xFLAG tag labelling of the protein of interest. 
The kit also provides the pAdEasy-1 vector, which encodes the E1/E3 deleted 
adenoviral genome and the homologous recombination sites. These plasmids are co-
transformed into the supplied BJ5183 RecA+ E.coli bacteria. The expectantly 
recombined plasmid is re-transformed into the also provided RecA- XL-Gold E.coli 
bacteria and amplified. Taking advantage of the rare cutter PacI, the linearized, new 
adenoviral genome is transfected into E1-trans complementing HEK 293 cells for 
virus production. 
 
 
Using standard cloning techniques as described in chapter II.2.4., the gene of 
interest was integrated into an adenoviral genome stepwise, following the schematic 
steps depicted in Figure 6.  
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Figure 6: Steps of adenovirus generation  
(adapted from pAdeasy kit, Stratagene, manual) 
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II.11.2. Expansion of recombinant adenovirus: 
 
After confirmed PacI linearization of the sequence verified plasmid, containing the 
target gene recombined to the adenoviral backbone, 293 cells of a 70% confluent 6-
well were transfected employing the Stratagene mammalian transfection kit.   
Therefore, 4 µg DNA was solved in 90µl water. 10µl Solution 1 and 100µl solution 2 
were very well mixed and added to the DNA under continuous mixing. The combined 
solutions were incubated at RT for 15 minutes and subsequently added to the cells 
drop wise. Cells were incubated at 37°C for 20 hours and then medium was 
changed. From this step on all following steps have to be made under precautions 
and working conditions adapted to handling security level two viruses.  
 
The progressions of the transfection and possibly propagating infections, which were 
visible by either a GFP reporter or plaque formation, had to be examined under the 
microscope daily. Medium of the cells should be changed considering the 
accommodation of the producing cells on one hand and an infection feasible virus-
concentration on the other hand.  
 
To propagate the infection and to expand the number of virus particles, a high 
number of 293 cells had to be infected. Therefore, a big flask of non-confluent 293 
cells was infected with primary virus lysate. This was prepared from the transfected 
cells, respectively, by a freeze-and-thaw procedure when first plaques appeared. 
The cells were harvested, collected by centrifugation, resuspended in HE- buffer 
(10mM HEPES, 1mM EDTA) and lysed by 3 cycles of repetitive freezing in liquid 
nitrogen and warming to 37°C in a water bath. The lysate was centrifuged at RT at 
11000rpm for 10 minutes. The viral particles were in the supernatant. The 
suspension has to be stored at –80°C.  
For infection of a big 175cm² flask of 293 cells approximately a tenth of the primary 
lysate was used depending on its infection grade. When this big flask was infected 
thoroughly but before it would have been lysed completely, the cells were harvested 
and treated like the primarily infected cells.  
Consequently, the resulting lysate was used to infect 40 big tissue plates of non-
confluent 293 cells for the final expansion step. The crucial point of this step is to 
keep the balance between a sufficiently high infection rate to prevent the cells from 
growing dense and a consequently metabolic shut down on one hand and an 
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abundant lysis of the cells due to substantially high infection on the other hand. 
Ideally, 293 cells of the 40 infected plates were allowed to produce viral particles 3-5 
days and were then lysed by 4 cycles of freeze-and-thawing consecutively.  
 
II.11.3. CsCl purification: 
 
As the virus will be used for infection of for example primary cells, the viral particles 
of this big prep lysate were purified by Cesiumchloride-density-centrifugation. 
Therefore, a cesiumchlorid density gradient of 1,33 and 1,45 in HE-buffer- had to be 
established in a 50ml ultracentrifugation tube to underlay the lysate with. It was made 
sure that there were no air bubbles potentially destroying the gradient. The tube was 
sealed cautiously and centrifuged for 3 hours at RT at 45000 rpm in the VTi 50 rotor 
of the ultracentrifuge. A virus particle containing, dark band should be visible and 
extracted with an injection needle. This suspension was reloaded into a 5ml 
ultracentrifugation tube, which was filled up with 1,33 CsCl-solution air-bubble free, 
and centrifuged overnight at RT at 50000 rpm in the VTi 65 rotor. Hereafter, again a 
dark band should be formed. The virus band was retrieved with a thin needle and 
purified from the salt solution by dialysis.  
 
The virus solution was filled directly into the slid-A-lizer cassette (Pierce) with the 
syringe and needle used for taking the band. The cassette was allowed to swim in 
500ml dialysis buffer; for 4 hours at 4°C first and left overnight in fresh dialysis buffer 
subsequently. Finally, the purified virus suspension was aliquoted into 2ml cryo-tubes 
and stored at –80°C. 
 
II.11.4. Titration of  the virus: 
 
The titer of the virus was determined in doubles with the Adeno-X Rapid Titer kit from 
Clontech according to the manufacturer’s instructions. In short, a well determined 
number of cells were infected with different dilutions of the virus. After 48 hours 
amount of produced shell proteins was detected with a visible antibody reaction. 
Thereby, titer could be calculated.  
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II.11.5. Sequencing of the virus: 
 
Virus-DNA was isolated with the Blood-Mini-kit (Qiagen) following the manufacturer’s 
protocol. Here, the cell lysate of a big flask was used to ensure that the sequence of 
the target gene in the viral particles has not changed unintentionally during virus 
expansion. On the DNA (40kb fragments) standard PCR was exerted with the 
pShuttle-IRES-hrGFP1 primers recommended by Stratagene. The fragment of the 
correct size was isolated from a low-melt-agarose-gel as described and sent in for 
sequencing. 
II.12. FACS analysis: 
 
In order to detect the reporter-GFP produced in pShuttle-MEF2C-IRES-hrGFP-
Adenovirus virally infected cells, classical staining or labelling became unnecessary 
and was therefore omitted here. As infected HUVEcells were in a bad shape and 
sensitive, cells were not scraped but trypsinized for harvesting.  The reaction was 
stopped with medium. Cells were washed with 1xPBS and centrifuged in lock-cap 
tubes to avoid virus spreading. Therefore, cells were fixed with 0,5ml 4% 
paraformaldehyde per 6-well for 15 minutes on ice as well. Cells were pelleted for 0,5 
minutes at 8000rpm and subsequently resuspended in 200µl ice cold 1x PBS.  
After transfer of the samples into FACS tubes, cells were analysed in the 
FACSCalibur machine.  
 
II.13. Matrigel- Assay: 
 
Matrigel (BectonDickinson) was thawed on ice in the refrigerator overnight. The 
matrigel was diluted with serum-free M199 medium and aliquoted in order to obviate 
repeated freeze-thawing. All materials used like pipettes, plates, tubes, needles or 
syringes have to be pre-cooled, preparations have to be done on ice or in a cold 
room. For a standard experiment 100µl of liquid Matrigel were cautiously dropped 
into a 48-well to avoid air bubbles. For gelatinizing, the Matrigel was incubated at 
37°C for at least 30 minutes.  
In the mean time 16 hours adenovirus-infected HUVECs of two 6-wells were 
trypsinized, counted and seeded in 500µl M199 medium complete at a concentration 
of 2,5*105 cells per well. HUVECs were allowed to form a network for 16 hours at 
37°C. Progress of tube formation was documented by photography. 
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II.14. Sprouting Assay: 
 
For the purpose of a sprouting assay spheroids of 400 HUVECs per 30µl drop were 
aspired. When adenovirus-infected cells are to be tested, they are infected 16 hours 
before harvesting for spheroid formation. Cells were infected with MOI 15. 
Principally, cells were trypsinized and counted. 150000 cells were resuspended in 
80% EGM complete medium and 20% methocel. Methocel had to be centrifuged 
previously for 2 hours at 4000rpm and only the supernatant was used. With a multi-
channel pipette drops of 30µl of the cells containing medium-methocel suspension 
were dispersed over the cover of a 150mm plate. The drops were incubated at 37° 
overnight hanging up-side-down.  
To collect the formed spheroids, they were washed with a 10% FBS-EZ containing 
PBS buffer and harvested carefully. The spheroids were centrifuged at 700 rpm for 5 
minutes. The supernatant was removed very cautiously.  
Two kinds of media were prepared for the following steps. Medium 1 contained 80% 
methocel and 20% FBS-EZ. For 1 gel 0.5ml of this medium was necessary. Medium 
2 consisted of rat-tail collagen diluted in 0.1% acidic acid and 10x Medium M199. 
Moreover, 90µl 1M HEPES buffer were added and 500µl 0.2N NaOH for 
neutralization. Amounts were adjusted for 8 gels, which will principally contain 0.5ml 
Medium 2 each. Note, after neutralization collagen started immediately to polymerize 
and had to be processed instantly.  
The collagen gels were casted into a 24-well-plate for suspension cells (Greiner). 
Previously, the surrounding wells were filled with 1ml PBS. This should avoid 
subsequent drying of the gels in the inner wells.  
The spheroids pellet was resuspended gently in Medium 1. This suspension is mixed 
in a 1:1 ratio with Medium 2. 1ml of this mix is filled quickly into an inner empty well, 
altogether 8 times. The gels were allowed to polymerize for 1 hour at 37°C. Finally, 
spheroids were stimulated. Therefore, 100µl basal medium containing VEGF for a 
final concentration of 50 ng/ ml were added. On the following day pictures were taken 
to record the sprouting behaviour of the spheroids. 
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III. Aims: 
 
The aim of this work was to investigate the role of the VEGF-induced MADS box 
transcription factor MEF2C in endothelial cells and angiogenesis. Therefore, 
expression and consequences of overexpression of MEF2C in endothelial cells had 
to be analysed with appropriate tools which had to be generated.  
As VEGF is a key regulator and main trigger of early angiogenesis, comprehension 
of the functions of VEGF-dependent proteins is of special interest to perceive the 
procedures involved in formation of new blood vessels.  
The particular aims were as follows: 
 
∗ Verify the MEF2C mRNA induction by VEGF in HUVEC by real time RT-PCR 
measurements 
 
∗ Generate recombinant adenoviruses for MEF2C overexpression studies 
 
∗ Evaluate the overexpression of MEF2C by the recombinant adenovirus and 
analyse the influence of MEF2C on VEGF-induction for certain genes in 
HUVEC by real time RT-PCR 
 
∗ Perform in vitro angiogenesis assays (“Matrigel assay” and “Sprouting assay”) 
during overexpression of MEF2C by the recombinant adenovirus. 
 
This work should contribute to the knowledge about the VEGF-regulated transcription 
factor MEF2C, provide the basis to study the expression patterns governed by 
MEF2C and give insights into the influence of MEF2C on angiogenesis on a cell 
physiological level. 
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IV. Results: 
 
The objective of this work was to elucidate the role of MEF2C in EC during 
angiogenesis. Therefore, the intended tasks were: i) to verify the VEGF dependent 
upregulation of MEF2C by real-time RT-PCR, ii) to construct a MEF2C-expressing 
and a corresponding control adenovirus, iii) to test these viruses in a matrigel assay 
and a sprouting assay and iv) to search for genes, which are modulated in their 
VEGF-inducibility by MEF2C. 
 
IV.1. Verification of MEF2C induction by VEGF in HUVEC: 
 
MEF2C was selected as a gene selectively upregulated by VEGF, but not by EGF 
and IL-1 from microarray data obtained by B. Schweighofer (PhD thesis in 
preparation). To verify this data, which indicated a significant upregulation of MEF2C 
at the 150 minutes time point, cDNA was produced for real-time RT-PCR. In short, 
HUVEC were stimulated with VEGF, bFGF, EGF and IL1 for 30 minutes, 60 minutes, 
150 minutes and 360 minutes. The RNA from these cells was isolated and served as 
a template for cDNA synthesis. cDNA was analysed by real-time PCR using purpose-
built primers for MEF2C and ß2-microglobulin for normalization. The used methods 
are described in detail in chapter II.9.  
Results shown in Figure 7A-D represent data obtained from 3 independently 
generated cDNA series, which were evaluated by real-time PCR twice. 
On average, MEF2C was induced by VEGF 3.7-fold at the 150 minutes time-point 
and persisted at this elevated level for at least 120 minutes. Upon bFGF stimulation 
MEF2C mRNA expression increased 1.9-fold already at 60 minutes, peaked at 150 
minutes with a 2.7-fold induction and declined afterwards to its basal level. EGF 
dependent MEF2C induction constantly remained on a very low level below a 2-fold 
induction. IL1 did not stimulate MEF2C mRNA expression at any time point. 
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Figure 7: VEGF specific induction of MEF2C 
Serum starved HUVEC in 6-well plates were stimulated for 30 min, 60 min, 150 min and 360min with 
50µg/ ml VEGF, bFGF or IL-1 or 25µg/ ml EGF. Then cDNA was synthesized. MEF2C expression was 
measured with MEF2C primers encompassing the exon-intron boarders 8-9. For calculation of the 
relative induction the expression of the housekeeping gene ß2-microglobulin was also determined. All 
values were normalized to ß2M. Results are displayed as fold induction, relative to the basal 
expression level of untreated cells. The standard deviation was calculated from data obtained from 3 
series of cDNA.  
 
IV.2. Generation of a MEF2C adenovirus: 
 
A fragment encompassing the coding region for MEF2C was cut out of a cDNA clone 
obtained from the RZPD with the help of the restriction enzymes NotI and SpeI. The 
fragment was subcloned into the shuttle vector pShuttle-IRES-hrGFP-1, which is part 
of the AdEasy™ Adenoviral Vector System kit from Stratagene®. To confirm the 
correct insertion the pShuttle-MEF2C-IRES-hrGFP-1 was sequenced with primers 
recommended by Stratagene. Afterwards, the plasmid was linearized with PmeI and 
dephosphorylated. In this form the pShuttle-MEF2C-IRES-hrGFP-1 was co-
The Role of MEF2C in Endothelial Cells 
 
47
transfected with the pAdEasy vector into E.Coli of the strain BJ5183 RecA+ by 
electroporation to obtain a recombinant adenovirus genome by bacterial homologous 
recombination. Successful recombination at either the ITRs or at the origins could be 
identified by PacI control restriction, which revealed a 3kb or a 4.5kb fragment, 
respectively, in combination with a 30kb fragment. In Figure 8 both types of positive 
recombination are depicted in comparison to an un-recombined pShuttle-MEF2C-
IRES-hrGFP-1 to distinguish unambiguously the sizes of the bigger fragments. A 
schematic representation of the recombination of the shuttle vector with the 
adenovirus plasmid is given in Materials and Methods and of the vectors in the 
Appendix. 
 
 
Figure 8: Identification of positively recombined clones 
After co-transfection of the pShuttle vector and the pAdEasy vector Kanamycin resistant clones were 
selected, grown, prepped and subsequently digested with PacI to select a positively recombined clone 
0,8% Agarose Gel for analysis of large-sized DNA 
Lane 1: 1kb Marker (see Appendix)  
Lane 2, 4 and 6: PacI digested individual plasmid clones pAdE.hrGFP.MEF2C-7 to 9 obtained after 
cotransfection of pAdEasy plasmid and pShuttle-MEF2C-IRES-hrGFP-1 into electro-competent E.Coli; 
bands sizes of 4.5kb corresponds to recombination at the origins 
Lane 3, 5 and 7: uncut plasmid preparation of clones pAdE.hrGFP.MEF2C-7 to 9 respectively 
Lane 8: PacI digested plasmid clone pAdE.hrGFP.MEF2C-10; positively recombined at the inverted 
terminal repeats corresponding to the band size 3kb 
Lane 9: uncut plasmid pAdE.hrGFP.MEF2C-10 
Lane 10: BstI lambda Marker (see Appendix) 
Lane 11: PacI digested pShuttle-MEF2C-IRES-hrGFP-1 plasmid preparation 
 
   1      2      3       4      5      6       7      8      9     10    11         
30 kb
8 kb 
3 kb
4.5 kb 
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After successful recombination the pAdE.hrGFP.MEF2C-7 DNA was sequenced 
again for control. Then the recombined large plasmid was isolated from a large scale 
preparation using the plasmid maxi purification kit from Quiagen. The plasmid was 
digested with PacI to expose the ITRs, which function as replication origins of the 
adenovirus in mammalian cells. Following linearization, the DNA was transfected into 
293 cells seeded in a 6-well-plate using the mammalian transfection kit from 
Stratagene®. Medium was changed partially every three days to keep the cells 
viable. Eleven days after transfection the first plaque was detected (Figure 9).  
Subsequently, when many plaques appeared, cells were scraped from the plate and 
lysed by freeze-thawing cycles. The viral particles isolated in this process were used 
for infection of 293 cells in bigger plates to amplify the virus. The final adenovirus 
containing cell lysate was purified by CsCl density gradient centrifugation.  
 
For the generation of the control adenovirus, all steps were performed similarly to the 
MEF2C expressing virus except the very first subcloning step of the gene of interest. 
The empty pShuttle-IRES-hrGFP-1 vector was recombined with the pAdEasy vector.  
 
The titres of both big viral preparations were determined with the AdenoRapidTitre kit 
from Clontech®. A titre of 6.5x108 pfu (plaque forming units)/ ml for the 
AdE.hrGFP.MEF2C and a titre of 5.0x109 pfu/ ml for the AdE.hrGFP.ctrl were 
assessed.  
All mentioned procedures and methods are described under II.11. in detail.  
 
 
Figure 9: Plaque formation  
293 cells were seeded into 6-well plates and grown to 70% confluence. They were transfected with a 
positively recombined pAdEasy-MEF2C-IRES-hrGFP-1 clone with the mammalian tranfection kit from 
Stratagene. Under the phase contrast microscope the first plaque appeared after eleven days (1). 
Under the fluorescence microscope transfected and infected cells were traced via the green 
fluorescence reporter protein (2). 
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IV.3. Determination of optimal MOI (Multiplicity of Infection): 
 
Investigations of cell signalling are very sensitive to experimental conditions. When 
cells are stressed unintentionally, the stress response can mask normal cell 
responses or activated signalling pathways. In comparison to standard transfection 
procedures infections with replication defective adenoviruses do not involve harsh 
treatment of the cells, but still can provoke inflammatory anti-viral responses (“virus 
effect”). Therefore, the exact MOI has to be defined, at which all cells are infected, 
but multiple infections are avoided to prevent excess viral effects.  
HUVEC were infected with AdE.hrGFP.ctrl with MOI of 1, 3, 10, 15, 30 and 100 for 
32 hours. Then the cells were analysed by FACS analysis as described in chapter 
II.12.. Figure 10A shows that already with MOI 10 nearly all cells were infected. With 
MOI 15 clearly 100% infection rates were achieved. 
Corresponding to an increasing MOI the mean fluorescence per cell also increased 
as it can be seen in Figure 10B. After the infection rate reached 100% saturation at 
MOI 10 to 15, the mean fluorescence per cell continued to increase further with 
higher MOIs and reached saturation level at about MOI 100.    
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Figure 10: Identification of Adenovirus Infection 
A. 106 HUVEC were counted and infected with control adenovirus pAdEasy-IRES-hrGFP-1 with MOI 1, 
3, 10, 15, 30 and 100 for 32 hours. They were harvested, fixed and evaluated by FACS analysis. 
B: The fraction of infected cells corresponds to the percentage of fluorescent cells of a sample. The 
mean fluorescence of the samples was recorded and charted automatically by the FACS machine and 
are expressed and displayed as relative values.  
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IV.4. Overexpression of MEF2C: 
 
To test the function of AdE.hrGFP.MEF2C the production of MEF2C mRNA and 
protein during infection was determined. To test whether the MEF2C virus generated 
the correct protein and when the protein starts to emerge, HUVEC were infected with 
MEF2 virus with MOI 15 for 4 hours, 8 hours, 16 hours, 32 hours and 48 hours, lysed 
with Lämmli buffer afterwards and subsequently subjected to Western blotting. 
As shown in Figure 11, after 4 and even 8 hours of infection hardly any MEF2C was 
noticeable. At the 16 hours time point the beginning of substantial translation of 
MEF2C became visible. After 32 and 48 hours a massive accumulation of MEF2C 
was detectable. 
 
 
Figure 11: Time course of MEF2C protein (44kDa) overexpression 
HUVEC were seeded into 12 well-plates and infected with AdE.hrGFP.MEF2C with MOI 15 for 4, 8, 
16, 32 and 48 hours. Then cells were lysed and resuspended in Lämmli buffer. These samples were 
subjected to SDS-PAGE and Western blotting and analysed with a polyclonal goat-anti-MEF2C-
antibody. 
  
To prove mRNA overexpression by the AdE.hrGFP.MEF2C HUVEC were infected 
with AdE.hrGFP.MEF2C and AdE.hrGFP.ctrl with MOI 15 for 16 hours and 
subsequently stimulated with VEGF for 30 min, 60 min and 150 min. Total RNA was 
isolated and subjected to cDNA synthesis. cDNA was evaluated by real time RT-
PCR.  
Evaluation of the cDNA revealed a typical induction pattern of MEF2C of around 3 
fold at 150 minutes after VEGF stimulation in HUVEC, which were not infected or 
infected with the AdE.hrGFP.ctrl. In comparison, cells that had been infected with the 
AdE.hrGFP.MEF2C showed levels of MEF2C mRNA about 1000-fold over the 
  4h     8h    16h   32h   48h    0 
44 kDa 
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endogenous levels without VEGF identification and lead not to any further induction 
by VEGF (Figure 12).  
The results confirm the MEF2C virus is able to overexpress MEF2C efficiently.  
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Figure 12: Testing of MEF2C mRNA overexpression 
Serum starved HUVEC seeded in 6-well plates were infected for 16 hours with MOI15 of control or 
MEF2C virus. Cells were induced with 50ng/ ml VEGF for 0 min, 30 min, 60 min or 150 min. The total 
RNA was isolated and subjected to cDNA synthesis. Real time RT-PCR was performed using the 
primers MEF2C_fw and MEF2C_rev for the quantification of MEF2C mRNA. Obtained real time RT-
PCR data were normalized to ß2-microglobulin as internal standard using the primers ß2M_fw and 
ß2_rev. Data were calculated from two series of experiments performed with single wells or duplicates 
wells, respectively. 
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IV.5. Influence of MEF2C on VEGF-mediated gene induction in HUVEC 
 
As MEF2C is a transcription factor, it was suggested that MEF2C overexpression 
might modulate the gene expression pattern of AdE.hrGFP.MEF2C infected cells. For 
studying angiogenesis it is of particular interest whether MEF2C might influence 
VEGF-stimulated gene induction in HUVEC.  
Therefore, serum starved HUVEC were infected with MEF2C virus and control virus 
with MOI 15 for 16 hours and subsequently stimulated with VEGF up to 150 min. 
Total RNA was isolated and served as template for cDNA synthesis. The cDNA was 
tested for several VEGF-regulated genes by real time PCR, using ß2Microglobulin 
expression for normalization.  
Many transcription factors downregulate their own expression in a negative feed-
back loop. This also seems to be the case with MEF2C. When the VEGF-dependent 
induction of the endogenous MEF2C was evaluated by real time PCR with the primer 
pair MEF2C_endo_fw and MEF2C_endo_rev, the result was very clear (Figure 13A). 
Endogenous MEF2C showed the usual expression pattern of 3- to 4-fold induction 
upon VEGF stimulation in the uninfected and in the control virus infected cells. In 
contrast, in the AdE.hrGFP.MEF2C infected cells endogenous MEF2C was already 
down-regulated in non-induced cells. Following VEGF treatment only little 
upregulation of MEF2C could be observed and MEF2C levels always remained 
below the basal level (set to 1) of uninfected and unstimulated cells. 
 
MMP10 has previously been reported to be a direct target of MEF2C. Therefore, 
expression of MMP10 during MEF2C overexpression was analysed. As shown in 
Figure 13B no VEGF-mediated induction was detected in any of the tested cells; the 
uninfected, the AdE.hrGFP.ctrl and the AdE.hrGFP.MEF2C infected cells. However, 
it was noticed that MMP10 exhibited significantly lower basal expression levels in the 
AdE.hrGFP.MEF2C infected cells in comparison to the control cells. 
 
DSCR1 and NR4A2 are among the most strongly induced genes by VEGF in 
HUVEC, which was shown by microarrays (B.Schweighofer, PhD thesis in 
preparation). Both proteins are upregulated in response to Ca2+-signalling and 
MEF2C was also reported to affect Ca2+-signalling. As Ca2+-signalling generally plays 
an import role in regulation of angiogenesis, influence of MEF2C overexpression on 
DSCR1 and NR4A2 was tested (Figure 13 C+D).  
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DSCR1 was induced by VEGF in uninfected cells at 30 minutes 22- to 30-fold. The 
control virus infected cells exhibited a virus effect as VEGF induction was decreased 
in comparison to uninfected cells, but cells still were inducible up to 10-fold.In 
contrast, VEGF could not mediate significant DSCR1 induction in AdE.hrGFP.MEF2C 
infected cells, DSCR1 mRNA expression remained on the basal level all the time.  
NR4A2 was strongly induced by VEGF in uninfected as well as in control virus 
infected HUVEC up to a 300-fold at 30 minutes, whereas in MEF2C overexpressing 
cells VEGF induction was strongly diminished to a much lower induction of 16-fold.  
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Figure 13 A-D: Modulation of endogenous MEF2C, MMP10, DSCR1 and NR4A2 
Serum starved HUVEC seeded in 6-well plates were infected for 16 hours with MOI15 of control or 
MEF2C virus. Cells were induced with 50ng/ ml VEGF for 0 min, 30 min, 60 min or 150 min. The total 
RNA was isolated and subjected to cDNA synthesis. Real time RT-PCR was performed using the 
primers MEF2C_endo_fw and MEF2C_endo_rec for the quantification of endogenous MEF2C (A), 
MMP10_fw  and MMP10_rev for MMP10 (B), DSCR1_fw and DSCR1_rev for DSCR1 (C) and 
NR4A2_fw and NR4A2_rev for NR4A2 (D). All obtained real time RT-PCR data were normalized to 
ß2Micoglobulin as internal standard using the primers ß2M_fw and ß2_rev. 
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IV.6. In vitro Angiogenesis Assays: 
 
To study the mechanisms of angiogenesis and to elucidate the function of the 
proteins involved, several angiogenesis assays provide a good opportunity to monitor 
endothelial cell behaviour in vitro under defined conditions. In the Matrigel assay the 
capacity of two dimensional tube formation can be tested. On Matrigel, an ECM-rich 
gel, endothelial cells spontaneously form networks. This can be modulated by 
angiogenesis enhancers like VEGF or potential inhibitors. When HUVEC are infected 
by adenoviruses overexpressing a certain gene the influence of this gene on 
angiogenesis can be analysed.  
In order to test the effects of MEF2C overexpression, HUVEC were infected with 
MEF2C or control virus for 16 hours, then harvested carefully and subsequently 
seeded onto Matrigel. Cell behaviour was monitored under the microscope for eight 
hours. At four hours the network seemed to be formed.  
As shown in Figure 14 no significant difference between the tube formation of 
uninfected, control virus infected or MEF2C virus infected cells could be observed. 
 
Since angiogenesis is defined as the formation of new vessels by sprouting from 
existent vessels the influence of a potential modulator on sprouting is important. The 
in vitro spheroid assay takes advantage of the phenomenon that endothelial cells 
form spheroids by attaching to each other when they are devoid of an adherent 
surface. When these spheroids are embedded into a collagen gel the endothelial 
cells on the surface of the spheroid spontaneously form sprouts. This can be strongly 
enhanced by angiogenic growth factors like VEGF. With this system angiogenesis 
regulating substances or genes can be tested.                                
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Figure 14: Matrigel Assay 
HUVEC were infected with MOI 15 of control or MEF2C virus for 16 hours, harvested and counted. 
Matrigel was thawed on ice, transferred into 48 wells a 4°C and subsequently allowed to gelatinize at 
37°C. HUVEC were seeded onto the matrigel and allowed to form a network for eight hours.  
A: Numbers of total branching points counted in triplicate wells 
B: Network formation documented under the phase contrast microscope.  
 
B 
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To elucidate the influence of MEF2C overexpression, HUVEC were infected with 
control or MEF2C virus and subsequently allowed to form spheroids by the hanging 
drop method. These spheroids were transferred into a matrix consisting of rat tail 
collagen for stabilization and medium solved methocel as a scaffold and nourishment 
supply. The spheroids were stimulated with VEGF overnight and then examined 
under the microscope. As example one spheroid of every condition is documented in 
Figure 15. 
VEGF stimulation positively enhanced sprout formation in the uninfected and also in 
the control virus infected cells as it is shown in Figure 15. A small reduction of sprout 
formation in the control virus infected cells is visible, but the adenovirus effect seems 
not to be critical. Strikingly, MEF2C virus infected cells do not exhibit any sprout 
formation, neither in the unstimulated samples nor in the VEGF stimulated samples. 
This inhibition of sprout formation was observed in every MEF2C overexpressing 
spheroid.  
 
 
Figure 15: Spheroid Assay 
HUVEC cells were infected with control virus or MEF2C virus for 16 hours, harvested and 
subsequently allowed to form spheroids by the hanging drop method. Therefore, the cells were 
resolved in 20% methocel and 80% medium. 30µl drops of the cell suspension were put on the lid of a 
dish and incubated overnight. The thereby formed spheroids were harvest carefully and embedded 
into a 1:1 matrix of rat tail collagen and methocel. They were stimulated with 50ng/ ml VEGF 
overnight. 
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V. Discussion: 
 
 
This work was focused on elucidating the role of the transcription factor MEF2C in 
endothelial cells during angiogenesis. MEF2C is a gene specifically induced by 
VEGF in endothelial cells and therefore assumed to be involved in angiogenesis. 
Angiogenesis is the formation of new (blood or lymph) vessels by sprouting from pre-
existing vessels. As many diseases like ischemic heart diseases or cancer are 
associated with pathological angiogenesis the processes involved in angiogenesis 
are topics of disease-related investigations. It is important to understand the 
molecular basis of the associated cellular regulation systems to be able to develop 
alternative therapies in the future. Since MEF2C is implicated to be a key player 
during development in other cell types, it seemed possible, that MEF2C plays a role 
in endothelial cells during angiogenesis. To support this hypothesis, specific 
upregulation of MEF2C upon VEGF induction had to be verified by real time RT-
PCR. Moreover, an adenovirus, which expresses MEF2C, had to be constructed as a 
basis to identify genes that are modulated by this transcription factor and to study its 
influence on angiogenesis assays. 
 
V.1. MEF2C is specifically upregulated by VEGF: 
 
In a microarray gene profiles of HUVEC were compared after treatment with the 
angiogenic growth factor VEGF, or the general growth factor EGF or the 
inflammatory cytokine IL-1. The hypothesis was that genes which are specifically 
upregulated by the angiogenic growth factor VEGF are potentially important for 
angiogenesis. When some of these genes in addition fulfil the criteria not to be 
induced by the general growth factor EGF or the inflammatory cytokine IL-1, they are  
likely neither part of the regular growth process nor the inflammatory response, but 
will rather accomplish a VEGF specific angiogenic function. Therefore it was 
concluded that these genes are potential candidates to be angiogenesis-specific 
genes. As we are interested especially into the initial process of sprouting, early time 
points of induction (30 min, 60 min, 150 min and 360 min) were selected for analysis. 
MEF2C is an example of a gene, which is specifically upregulated by VEGF with 
peak values at 150 min. 
From microarrays broad information can be obtained, but exact quantification is 
limited. Therefore, potentially interesting results have to be verified quantitatively with 
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another reliable method; here with real time RT-PCR. The obtained results for 
MEF2C confirmed that the microarray results were correct, because a VEGF-
dependet 3.7-fold upregulation at 150 min of stimulation was determined (Figure 7). 
MEF2C seems not to be an immediate early gene, which usually peak at 30-60 
minutes, but to belong to a group of second wave genes revealing peak values 
between 2-4 hours. Real time RT-PCR also revealed that MEF2C was slightly 
induced by bFGF, which is also an angiogenic growth factor. This substantiated the 
notion that MEF2C is involved in angiogenesis.  
 
V.2. The experimental tool adenovirus: 
 
Standard methods of transfections of plasmid DNA into mammalian cells do not work 
efficiently for HUVEC. Additionally, such procedures can violate the cells’ 
constitutions to an unacceptable extent for physiologic assays.  
Therefore, a MEF2C encoding adenovirus was constructed. Thereby MEF2C could 
be overexpressed in HUVEC which were used for angiogenesis assays 
subsequently. An appropriately high infection rate ascertains that 100% of the cells 
can be transduced by the recombinant virus. The use of a reporter gene like that for 
the green fluorescent protein facilitates to control the infection efficiency. It was 
therefore decided to generate an adenovirus which encodes a GFP under the control 
of an IRES following the gene-of-interest (MEF2C) in the viral construct. This avoids 
potential problems which could arise from a directly GFP labelled fusion protein of 
interest when the label disturbs its function. Likewise also an his-tag was abandoned 
which would have been provided on the vector pShuttle-IRES-hrGFP-1 from 
Stratgene®. This shuttle vector is part of the pAdEasy kit. With the help of this kit a 
complete adenovirus can be generated (Figure 6).  
The central mechanism of this system is the homologous recombination (for 
schematic depiction of the reaction see Materials and Methods) in bacteria of a 
shuttle vector, which contains the coding sequence of MEF2C (for schematic 
depiction of the construct see Appendix), and the vector encoding the adenoviral 
genome after co-transfection. The coding sequence of MEF2C’s cDNA (for sequence 
see Appendix), including the START and STOP codon, was subcloned into the MCS 
of the pShuttle vector. Thereby it came under the control of the very strong CMV 
promoter. At the 3’ side it is followed by the IRES, the GFP cDNA and a SV40 
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polyadenylation site. These conditions ensured an efficient mRNA production 
subsequently. 
The crucial step in the generation of the adenovirus was the selection of positively 
recombined clones. The two plasmids can recombine at two regions: the origins of 
replication or the ITRs (Figure 6). Two patterns of DNA fragments are obtained from 
clones after PacI digestion. Along with a 30kb fragment either a 4.5kb (ori) or a 3kb 
(ITRs) fragment emerges. But a 3kb fragment can also derive from a non-
recombined clone along with an 8kb fragment (pShuttle vector backbone). To ensure 
to select a positively recombined construct, clone pAdE-MEF2C-IRES-hrGFP-7, 
which showed a 4.5kb fragment, was sequenced (Figure 8). This was necessary, 
since recombination events are error prone and could produce mutations.  
The MEF2C coding sequence was found to be correct. Then clone pAdE-MEF2C-
IRES-hrGFP-7 was transfected into 293 cells, which can be transfected efficiently. 
The DNA had to be digested with PacI to expose the ITRs. Otherwise the circular 
adenoviral genome would not be replicated in the host cells. After transfection only a 
small number of viral particles form. When they finally lyse the cells they re-infect the 
local neighbour cells. Thus a plaque, a hole in an otherwise dense cell layer, forms. 
From clone pAdE-MEF2C-IRES-hrGFP-7 a first plaque was formed 11 days after 
transfection (Figure 9). Subsequently, when cells were infected with a high virus 
concentration all cells died concomitantly and plaques were not observed. 
Adenovirus particles were amplified and subsequently purified. Finally, titres of 
6.5x108 pfu/ml for the AdE.hrGFP.MEF2C and 5.0x109 pfu/ml for the AdE.hrGFP.ctrl 
were obtained. 
In parallel to the AdE.hrGFP.MEF2C virus a control virus was generated. It encoded 
GFP, but did not contain the MEF2C. A control virus is necessary for experiments to 
be able to exclude virus effects. Also the overexpressed GFP might cause effects, 
which can be dissected by the control virus. 
 
Whether the adenovirus AdE.hrGFP.MEF2C overexpresses MEF2C mRNA efficiently 
in HUVEC and the correct protein, was tested by real time RT-PCR and Western 
blotting, respectively. MEF2C mRNA accumulated in AdE.hrGFP.MEF2C infected 
cells to levels about 1000-fold higher than in uninfected cells.  
A time-course experiment monitored accumulation of MEF2C protein in 
AdE.hrGFP.MEF2C infected HUVEC. As the anti-MEF2C antibody detected a protein 
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of the correct size, the protein was regarded to be expressed correctly (Figure 11). 
The experiment also revealed that a significant amount of protein can already be 
detected after 16 hours of infection while hardly any protein was measured in the first 
8 hours of infection. After 32 hours very high amounts of protein were present in the 
cells; likewise after 48 hours. Consequently, we had to consider the appropriate 
protein-dose which would meet the demanded experimental conditions. On the one 
hand, too much of one protein could cause a cell to behave differently and atypically 
alone because of the overload. On the other hand, at the beginning of a steeply 
increasing expression rate a small variation in time-points leads to big differences in 
protein concentrations. This could influence the results of experiments also. 
Therefore, it was decided to infect HUVEC for 16 hours before they were used for 
experiments.  
 
As HUVEC do not trans-complement E1/E3 deficient adenoviruses like 293 cells, 
adenoviruses cannot replicate. Thus, HUVEC are not lysed but only express the 
introduced gene-of-interest. Nevertheless, these HUVEC suffer from an infection. 
The viral particles can elicit an inflammatory response. Moreover, massive 
overexpression of a protein itself can disturb a cell in its normal function. Therefore, it 
is necessary to find a balance between a 100% infection rate and prevention of vast 
multiple infections. Especially these can induce a viral effect, which can lead for 
example to a preliminarily changed expression profile for many genes in the tested 
cells. When signalling pathways are under investigation this effect can simulate or 
mask induction.  
Therefore, in this work different MOI (1, 3, 10, 15, 30 and 100) were tested on 
resulting infection rates. Infection rate was determined in a FACS analysis via the 
GFP protein encoded by the adenovirus. It became evident that already with MOI 10 
nearly all and with MOI 15 100% of the cells were infected (Figure 10). In many 
publications MOI 100 is employed. In our experiments cells exhibited a mean 
fluorescence at MOI 100 10 times higher than at MOI 10 reflecting multiple infections 
per cell. These numbers suggest that delivery of one viral expression unit into 
HUVEC requires at least 10 viral particles per cell; 10 pfu established in 293 cells. 
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V.3. Influence of MEF2C on VEGF induced genes: 
 
Angiogenesis comprises several cellular processes which are supposed to be tightly 
regulated. MEF2C is a transcription factor which is specifically upregulated upon 
VEGF stimulation. The pattern of genes which are modulated by MEF2C could 
therefore provide evidence about the role of MEF2C in the orchestration of 
angiogenesis.  
 
While many transcription factors activate the transcription of other genes they 
frequently down-regulate their own transcription in a negative feed-back loop. Here it 
was shown by real time RT-PCR that MEF2C exhibited a similar behaviour. The 
endogenous MEF2C was diminished below the control basal level of untreated cells 
in all AdE.hrGFP.MEF2C infected HUVEC (Figure 13A). Additionally, endogenous 
MEF2C was not VEGF inducible anymore whereas untreated and control infected 
cells still displayed the usual induction of 3- to 4-fold upon VEGF stimulation. It is 
likely that the MEF2C gene is repressed by a protein upregulated by MEF2C 
overexpression. 
 
To test a target of MEF2C described for SMC, MMP10 was analysed during MEF2C 
overexpression. As MMPs play an important role during the remodelling processes of 
angiogenesis, it would be interesting to know whether MEF2C regulates such genes 
in EC. It has been described previously, that MMP10 is activated by MEF2C in SMC 
when it is not repressed by HDAC7 (Chang et al., 2006). Therefore, it seemed 
possible that the high amount of MEF2C in infected cells might titre out the 
repressing HDAC7 and MMP10 would be upregulated. However, in our experiments 
MMP10 was not induced by VEGF in HUVEC (Figure 13B) and it was remarkable 
that MMP10 levels in AdE.hrGFP.MEF2C infected cells were persistently reduced 
compared to the uninfected or the control virus infected cells. The potential response 
induced by MEF2C to repress further MEF2C expression in a negative feed-back 
loop, might also inhibit expression of some other genes such as MMP10. 
 
DSCR1 and NR4A2 are prominent examples for very early specifically VEGF 
induced genes. Their VEGF-dependent inducibility under the influence of MEF2C 
was tested. Similar to data from the microarray of B. Schweighofer (PhD thesis in 
preparation) DSCR1 and NR4A2 were strongly induced upon 30 minutes of VEGF 
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stimulation in uninfected or control virus infected cells. DSCR1 induction was 
sensitive to virus infection because it was induced only 10-fold in the control virus 
infected cells but 25-fold in uninfected cells. This was not the case for NR4A2, which 
was highly upregulated 300-fold and also control virus infected cells exhibited an 
equal activation. Strikingly, neither DSCR1 nor NR4A2 remained VEGF inducible in 
the AdE.hrGFP.MEF2C infected cells (Figure 13C+D). MEF2C overexpression 
specifically silenced DSCR1 and NR4A2 induction.  
A possible interconnection of MEF2C, DSCR1 and NR4A2 is the Ca2+ signalling as 
described in several publications: DSCR1 is the negative regulator of the important 
transcription factor NFAT, because it blocks calcineurin which activates NFAT by 
dephosphorylation (Hogan et al., 2003). NFAT is a very important regulator of 
endothelial cells. As an integrative part of a negative feed-back loop the DSCR1 
promoter contains NFAT binding sites. DSCR1 is upregulated by NFAT and in turn 
inhibits further NFAT activation by calcineurin.  
MEF2C was described to have an influence on intracellular Ca2+ release by 
regulating the Ca2+ chaperon calreticulin in the ER in a positive feed-back loop. It 
activates calreticulin transcription, which can further lead to sustained Ca2+ supply 
and in turn (due to a thereby exposed NLS) to extended MEF2C nuclear 
translocation (Lynch et al., 2005), where it might further enhance calreticulin 
transcription.  
Albeit, Ca2+ seems to be a powerful regulator of MEF2C via other direct as well as 
indirect mechanisms; for example HDACs are phosphorylated by Ca2+/Calmodulin 
dependent kinases, and thereby loose their repressing influence on MEF2C when 
they are consecutively exported from the nucleus (McKinsey et al., 2002). Moreover, 
MEF2 proteins were reported to cooperate with the Ca2+ dependent NFAT, thereby 
enhancing a signal (Youn et al., 2000). For example MEF2 proteins can activate the 
NR4A proteins also in co-operation with NFAT (Martinez-Gonzalez and Badimon, 
2005).  
The strongly VEGF-inducible NR4A2 is member of the orphan receptor family NR4A. 
The highly homologous proteins NR4A1-3 are probably active without a ligand. There 
are substantial indications that these transcription factors are involved in different 
developmental processes, but their explicit targets are unknown so far (Maxwell and 
Muscat, 2006). Recent reports connect NR4A proteins with vascular diseases 
empirically (Pols et al., 2007). NR4A1 and NR4A3 were studied in different cell types 
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but especially NR4A2 remains to be further investigated in endothelial cells to 
elucidate the molecular basis of these incidences. 
Although no fully coherent scheme of potential interactions between DSCR1, MEF2C 
and NR4A2 can be conceived yet, the specificity of the inhibition by MEF2C is 
substantial and therefore suggestion of a connection might be tantalizing.  
 
 
V.4. Angiogenesis assays: 
 
Several methods are established to test angiogenesis (Auerbach et al., 2003). There 
are in vitro assays as well as in vivo assays. In vivo assays provide physiologic 
conditions but are more labor-intensive. Therefore, for preliminary experiments in 
vitro assays are chosen. In the Matrigel assay tube formation capacity of endothelial 
cells can be tested, because they spontaneously form networks on this ECM-rich 
matrix. The spheroid assay provides three dimensional conditions to test the sprout 
formation capacity of endothelial cells (Korff and Augustin, 1998). 
 
On Matrigel it was tested whether MEF2C has an influence on the network-forming 
capacity of HUVEC cells to find out whether MEF2C plays an enhancing or an 
inhibitive role in angiogenesis. However, no significant differences could be observed 
between the control cells or the MEF2C expressing cells (Figure 14B). Both formed 
similar numbers of branches in the network (Figure 14A). It seems that MEF2C 
overexpression does not significantly affect tube formation on Matrigel. 
 
It was further tried to show whether MEF2C inhibits or stimulates sprout formation in 
a spheroid assay. The formation of sprouts protruding from an endothelial cell 
spheroid can be promoted by VEGF. The control cells (uninfected and 
AdE.hrGFP.ctrl infected) produced more sprouts when they were induced with VEGF 
(Figure 15). In contrast, the AdE.hrGFP.MEF2C infected cells displayed diminished 
sprout formation and no stimulation by VEGF was detected. Sprout formation 
seemed to be inhibited in AdE.hrGFP.MEF2C infected cells. 
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The results from the spheroid assay are in accordance with the results of the real 
time RT-PCR displaying reduced MMP10 and NR4A2 induction after infection with 
AdE.hrGFP.MEF2C and suggest that MEF2C, when overexpressed, might rather be 
an angiogenesis inhibitor.  
We can conceive several potential reasons for this finding. Angiogenesis is a process 
involving cell activation and proliferation and remodelling of the extracellular vicinity. 
Usually, negative feed-back loops mechanism should prevent hazardous 
overreactions of such processes. For example similar to inflammation, a process also 
inducing cell activation, it is suggested, that concomitantly with the initiation of 
angiogenesis also the subsequent termination of the process is already primed. 
Frequently, some of the genes of the second wave of induction upon an activating 
stimulus are inhibitors, which will limit the reaction in time. Therefore it seems 
possible that the angiogenic growth factor VEGF also induces inhibitory genes and 
MEF2C might be part of a negative feed-back loop. This is in accordance with 
MEF2C being induced at the rather late time points of 150 minutes until at least 360 
minutes after stimulation.  
Another aspect might be that angiogenesis is such a complex and intricate process 
that testing of a single player by overexpression may perturb the system. It is also 
possible, that necessary interaction partners of MEF2C are missing or not expressed 
in appropriate amounts and thereby overexpressing MEF2C may not score the 
normal functions. To singly overexpress one distinctive component of a usually 
coordinated functional network of proteins in a cell might cause severe problems in 
the execution of the normal temporal and spatial order of events. Due to the 
overexpression MEF2C might not be fully integrated into a probably important 
nuclear shuttling system or reaction partners might allocate at the wrong time. 
However, it seems that MEF2C overexpression is not toxic to the cells or would 
induce apoptosis, since no effect on tube formation on Matrigel was observed. 
Furthermore, it has to be considered that inhibitors might be required for the fine-
tuning of angiogenesis. For example, for correct sprout formation in a vessel EC 
have to ascertain that only the leading cell on the growing sprout is committed to 
become a tip cell, whereas additional sprouting of the cells in the stem region needs 
to be suppressed. In this regard it was shown for another VEGF-inducible gene, 
HLX1, that it specifically induces repulsive receptors in EC and therefore blocks 
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sprouting (Mag. Julia Schultes, unpublished data). A similar mechanism is also 
conceivable for MEF2C. 
Nevertheless, in the case of MEF2C it remains to be confirmed that the factor 
primarily has inhibitory function and this is not consequence of overexpression. 
Additional evidence should be obtained by testing downmodulation of MEF2C, which 
then should give complimentary results, i.e. stronger stimulation of gene transcription 
and sprouting. Knock-down by means of RNA interference might be the preferable 
method. Another possibility would be the use of a dominant-negative protein to block 
endogenous MEF2C function. These experiments should show that the inhibition not 
simply reflects a general functional shut down due to protein overload by the 
overexpressed MEF2C. Although relative specificity of the repression through 
MEF2C was observed in the real time RT-PCR experiments, where this inhibition 
was specific for certain genes, further data on cellular processes such as 
proliferation, apoptosis or migration will be required under conditions of MEF2C 
overexpression and knock-down. Moreover, a microarray could provide additional 
information about genes which are directly upregulated (or downregulated) by 
MEF2C. 
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VII. Appendix: 
VII.1. Vectors: 
VII.1.1. pShuttle-IRES-hrGFP-1 
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VII.1.2. pAdEasy-1: 
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VII.1.3. pBluescriptR-IRATp970F1023D: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Role of MEF2C in Endothelial Cells 
 
76
VII.1.4. pShuttle-CMV-MEF2C-IRES-hrGFP: 
 
 
The MEF2C coding sequence (2kb) was inserted into the pShuttle-IRES-hrGFP MCS 
vector after NotI and SpeI digestion. 
 
 
VII.2. Sequences: 
 
VII.2.1. Amino Acid sequence of MEF2C: 
 
     MGRKKIQITR IMDERNRQVT FTKRKFGLMK KAYELSVLCD CEIALIIFNS TNKLFQYAST   60 
     DMDKVLLKYT EYNEQHESRT NSDIVETLRK KGLNGCDSPD PDADDSVGHS PESEDKYRKI  120 
     NEDIDLMISR QRLCAVPPPN FEMPVSIPVS SHNSLVYSNP VSSLGNPNLL PLAHPSLQRN  180 
     SMSPGVTHRP PSAGNTGGLM GGDLTSGAGT SAGNGYGNPR NSPGLLVSPG NLNKNMQAKS  240 
     PPPMNLGMNN RKPDLRVLIP PGSKNTMPSV SEDVDLLLNQ RINNSQSAQS LATPVVSVAT  300 
     PTLPGQGMGG YPSAISTTYG TEYSLSSADL SSLSGFNTAS ALHLGSVTGW QQQHLHNMQP  360 
     SALSQLGACT STHLSQSSNL SLPSTQSLNI KSEPVSPPRD RTTTPSRYPQ HTRHEAGRSP  420 
     VDSLSSCSSS YDGSDREDHR NEFHSPIGLT RPSPDERESP SVKRMRLSE              469 
// 
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VII.2.2 Sequence of the MEF2C virus construct: 
 
tggagctcca ccgcggtggc ggccgcataa cttcgtatag catacattat acgaagttat       60 
ggatcaggcc aaatcggccg agctcgaatt cgtcgagagc gggctcccat cgcgcgcaca      120 
cacgcacaca tcgtctccag ctctctgctc gctctgctcg cagtcacaga cacttgagca      180 
cacgcgtaca cccagacatc ttcgggctgc tattggattg actttgaagg ttctgtgtgg      240 
gtcgccgtgg ctgcatgttt gaatcaggtg gagaagcact tcaacgctgg acgaagtaaa      300 
gattattgtt gttatttttt ttttctctct ctctctctct taagaaagga aaatatccca      360 
aggactaatc tgatcgggtc ttccttcatc aggaacgaat gcaggaattt gggaactgag      420 
ctgtgcaagt gctgaagaag gagatttgtt tggaggaaac aggaaagaga aagaaaagga      480 
aggaaaaaat acataatttc agggacgaga gagagaagaa aaacggggac tatggggaga      540 
aaaaagattc agattacgag gattatggat gaacgtaaca gacaggtgac atttacaaag      600 
aggaaatttg ggttgatgaa gaaggcttat gagctgagcg tgctgtgtga ctgtgagatt      660 
gcgctgatca tcttcaacag caccaacaag ctgttccagt atgccagcac cgacatggac      720 
aaagtgcttc tcaagtacac ggagtacaac gagccgcatg agagccggac aaactcagac      780 
atcgtggaga cgttgagaaa gaagggcctt aatggctgtg acagcccaga ccccgatgcg      840 
gacgattccg taggtcacag ccctgagtct gaggacaagt acaggaaaat taacgaagat      900 
attgatctaa tgatcagcag gcaaagattg tgtgctgttc cacctcccaa cttcgagatg      960 
ccagtctcca tcccagtgtc cagccacaac agtttggtgt acagcaaccc tgtcagctca     1020 
ctgggaaacc ccaacctatt gccactggct cacccttctc tgcagaggaa tagtatgtct     1080 
cctggtgtaa cacatcgacc tccaagtgca ggtaacacag gtggtctgat gggtggagac     1140 
ctcacgtctg gtgcaggcac cagtgcaggg aacgggtatg gcaatccccg aaactcacca     1200 
ggtctgctgg tctcacctgg taacttgaac aagaatatgc aagcaaaatc tcctccccca     1260 
atgaatttag gaatgaataa ccgtaaacca gatctccgag ttcttattcc accaggcagc     1320 
aagaatacga tgccatcagt gtctgaggat gtcgacctgc ttttgaatca aaggataaat     1380 
aactcccagt cggctcagtc attggctacc ccagtggttt ccgtagcaac tcctacttta     1440 
ccaggacaag gaatgggagg atatccatca gccatttcaa caacatatgg taccgagtac     1500 
tctctgagta gtgcagacct gtcatctctg tctgggttta acaccgccag cgctcttcac     1560 
cttggttcag taactggctg gcaacagcaa cacctacata acatgccacc atctgccctc     1620 
agtcagttgg gagcttgcac tagcactcat ttatctcaga gttcaaatct ctccctgcct     1680 
tctactcaaa gcctcaacat caagtcagaa cctgtttctc ctcctagaga ccgtaccacc     1740 
accccttcga gatacccaca acacacgcgc cacgaggcgg ggagatctcc tgttgacagc     1800 
ttgagcagct gtagcagttc gtacgacggg agcgaccgag aggatcaccg gaacgaattc     1860 
cactccccca ttggactcac cagaccttcg ccggacgaaa gggaaagtcc ctcagtcaag     1920 
cgcatgcgac tttctgaagg atgggcaaca tgatcagatt attacttact agtttttttt     1980  
 
The restriction sites NotI (gc^ggcc^gc) and SpeI (a^ctag^t) are depicted in green. 
Start- and Stop codon, atg and tga respectively, of the coding sequence are 
coloured in red. The sequence segment derived from the multiple cloning site of the 
MEF2C expressing pBluescriptR vector is marked in italic letters. 
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VII.3. Markers: 
VII.3.1. DNA Markers: 1kb DNA ladder and Lambda DNA/Eco91I (BstEII) digest  
 
 
 
 VII.3.2 Protein Marker: 
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VII.4. Abbreviations: 
 
Ang1 Angiopoetin 1 
bFGF basic fibroblast growth factor  
bp base pair 
cDNA complementary DNA 
CsCl cesium chloride 
DNA Desoxyribonucleic acid 
DSCR1 Down Syndrom critical region 1 
EC endothelial cells 
ECM extracellular matrix 
E. coli Escherichia coli 
EGF epidermal growth factor 
FCS Fetal calf serum 
GFP green fluorescent protein 
HUVEC human umbilical vein endothelial cells 
IL-1 interleukin 1 
IRES internal ribosomal entry site 
ITR inverted terminal repeat 
LPS lipopolysaccharides 
MAPK mitogen activated protein kinases 
MCS multiple cloning site 
min minutes 
MMP10 metallo matrix protease 10 
mRNA messenger ribonucleic acid 
NES nuclear export signal 
NR4A2 orphan nuclear receptor subgroup 4  
PBS phosphate buffered saline 
PDGF-BB platelet derived growth factor 
pfu plaque forming unit 
real-time RT-PCR real-time reverse transcription-polymerase chain reaction 
rpm revolutions per minute 
ROS reactive oxygen species 
RT room temperature 
SDS Sodium Dodecylsulphat 
sec seconds 
SMC  smooth muscles cells 
TGFß-1 tumour growth factor beta 1 
VEGF vascular endothelial growth factor 
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Summary: 
 
VEGF (Vascular endothelial growth factor) is the major regulator of the formation of 
new vessels by sprouting from pre-existing ones, a process termed angiogenesis. 
MEF2C (Myocyte Enhancing Factor 2) is a transcription factor, which was shown by 
microarray analysis to be specifically upregulated by VEGF in endothelial cells. This 
work generated the necessary experimental tools and investigated the regulation and 
potential role of MEF2C in endothelial cells during angiogenesis.  
In a first step it was confirmed by real time RT-PCR that MEF2C is selectively 
upregulated 3- to 5-fold by VEGF, but not by the general growth factor EGF or the 
inflammatory cytokine IL-1. Then a recombinant adenovirus was engineered to 
achieve overexpression of MEF2C in human umbilical vein endothelial cells 
(HUVEC). Using this adenovirus the influence of MEF2C on VEGF-mediated 
upregulation of several genes was analysed by real time RT-PCR. It was found that 
MEF2C not only suppressed the expression of the endogenous MEF2C, but also 
inhibited the upregulation of the strongly VEGF-inducible DSCR1 and NR4A2 genes. 
In accordance with the inhibitory action on major VEGF-inducible gene, MEF2C 
inhibited sprouting in the in vitro spheroid sprout formation assay. Tube formation in 
the in vitro Matrigel assay however seemed unaffected.  
These data suggest that MEF2C may function to downmodulate gene expression 
and sprout formation after VEGF treatment in a negative feed-back loop. 
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Zusammenfassung: 
 
VEGF (Vascular endothelial growth factor) ist der Hauptregulator für die Ausbildung 
neuer Gefäße aus bereits bestehenden durch Sprossung. Dieser Prozess wird 
Angiogenese genannt. MEF2C (Myocyte Enhancing Factor 2C) ist ein 
Transkriptionsfaktor, von dem mittels Microarray Analyse gezeigt wurde, dass er in 
Endothelzellen speziell durch VEGF hoch reguliert wird. Im Zuge dieser Arbeit 
wurden die notwendigen Konstrukte hergestellt und die Regulierung und mögliche 
Rolle von MEF2C in Endothelzellen während der Angiogenese untersucht.  
Zuerst wurde mittels real time RT-PCR bestätigt, dass MEF2C speziell von VEGF    
3- bis 5-fach hochreguliert wird, aber nicht vom allgemeinen Wachstumsfaktor EGF 
oder dem Entzündungsmediator IL-1. Danach wurde ein rekombinanter Adenovirus 
produziert, um eine Überexpression von MEF2C in HUVEC (menschliche 
Nabelschnur Endothelzellen) zu erreichen. Unter Verwendung dieses Adenovirus 
wurde der Einfluss von MEF2C auf die VEGF-vermittelte Hochregulierung  einer 
Auswahl an Genen mittels real time RT-PCR analysiert.Die Ergebnisse zeigen, dass 
MEF2C nicht nur die Expression des endogenen MEF2C unterdrückt, sondern auch 
die Hochregulierung der stark VEGF-induzierbaren Gene DSCR1 und NR4A2 
inhibiert. In Übereinstimmung mit der inhibitiven Wirkung auf wichtige VEGF-
induzierbare Gene, hemmte MEF2C auch die Aussprossung im in vitro „spheroid 
sprout formation assay“. Die Netzwerkbildung im in vitro „Matrigel assay“ blieb durch 
MEF2C aber unverändert . 
Diese Daten indizieren, dass MEF2C im Rahmen einer negativen Rückkopplung die 
Genexpression und die Ausbildung von Aussprossungen nach VEGF Behandlung 
reprimiert.  
